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In this review an overview is given on antibiotic resistance (AR) mechanisms with special
attentions to the AR genes described so far preceded by a short introduction on the dis-
covery and mode of action of the different classes of antibiotics. As this review is only
dealing with acquired resistance, attention is also paid to mobile genetic elements such as
plasmids, transposons, and integrons, which are associated with AR genes, and involved
in the dispersal of antimicrobial determinants between different bacteria.
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INTRODUCTION
The discovery and production of (synthetic) antibiotics in the ﬁrst
half of the previous century has been one of medicine’s greatest
achievements. The use of antimicrobial agents has reduced mor-
bidity and mortality of humans and contributed substantially to
human’s increased life span. Antibiotics are, either as therapeutic
or as prophylactic agents, alsowidely used in agricultural practices.
The ﬁrst discovered antimicrobial compound was penicillin
(Flemming, 1929) a β-lactam antibiotic. Soon after this very
important discovery, antibiotics were used to treat human infec-
tions starting with sulfonamide and followed by the aminoglyco-
side streptomycin and streptothricin (Domagk, 1935; Schatz and
Waksman, 1944). Nowadays numerous different classes of antimi-
crobial agents are known and they are classiﬁed based on their
mechanisms of action (Neu, 1992). Antibiotics can for instance
inhibit protein synthesis, like aminoglycoside, chloramphenicol,
macrolide, streptothricin, and tetracycline or interact with the syn-
thesis of DNA and RNA, such as quinolone and rifampin. Other
groups inhibit the synthesis of, or damage the bacterial cell wall
as β-lactam and glycopeptide do or modify, like sulfonamide and
trimethoprim, the energy metabolism of a microbial cell.
Upon the introduction of antibiotics it was assumed that the
evolutionof antibiotic resistance (AR)was unlikely. Thiswas based
on the assumption that the frequency of mutations generating
resistant bacteria was negligible (Davies, 1994). Unfortunately,
time has proven the opposite. Nobody initially anticipated that
microbes would react to this assault of various chemical poi-
sons by adapting themselves to the changed environment by
developing resistance to antibiotics using such a wide variety
of mechanisms. Moreover, their ability of interchanging genes,
which is now well known as horizontal gene transfer (HGT)
was especially unexpected. Later on it was discovered that the
emergence of resistance actually began before the ﬁrst antibiotic,
penicillin, was characterized. The ﬁrst β-lactamase was identi-
ﬁed in Escherichia coli prior to the release of penicillin for use in
medical practice (Abraham and Chain, 1940). Besides β-lactams,
the aminoglycoside–aminocyclitol family was also one of the ﬁrst
groups of antibiotics to encounter the challenges of resistance
(Wright, 1999; Bradford, 2001). Over the years it has been shown
by numerous ecological studies that (increased) antibiotic con-
sumption contributes to the emergence of AR in various bacterial
genera (MARAN, 2005, 2007; NethMap, 2008). Some examples
of the link between antibiotic dosage and resistance development
are the rise of methicillin-resistant Staphylococcus aureus (MRSA)
and vancomycin-resistant enterococci (VRE). The initial appear-
ance of MRSA was in 1960 (Jevons et al., 1963), whereas VRE were
ﬁrst isolated about 20 years ago (Uttley et al., 1988). Over the last
decades they have remained a reason for concern, but additional
public health threats in relation to resistant microorganisms have
also arisen (see for example Cantón et al., 2008; Goossens, 2009;
Allen et al., 2010).
Bacteria have become resistant to antimicrobials through a
number of mechanisms (Spratt, 1994; McDermott et al., 2003;
Magnet and Blanchard, 2005; Wright, 2005):
I. Permeability changes in the bacterial cell wall which restricts
antimicrobial access to target sites,
II. Active efﬂux of the antibiotic from the microbial cell,
III. Enzymatic modiﬁcation of the antibiotic,
IV. Degradation of the antimicrobial agent,
V. Acquisition of alternative metabolic pathways to those inhib-
ited by the drug,
VI. Modiﬁcation of antibiotic targets,
VII. Overproduction of the target enzyme.
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TheseAR phenotypes can be achieved in microorganisms by chro-
mosomal DNA mutations, which alter existing bacterial proteins,
through transformation which can create mosaic proteins and/or
as a result of transfer and acquisition of new genetic material
between bacteria of the same or different species or genera (Spratt,
1994; Maiden, 1998; Ochman et al., 2000).
There are numerous examples of mutation based resistance.
For example,macrolide resistance can be due to nucleotide(s) base
substitutions in the 23S rRNA gene. However, a similar resistance
phenotype may also result from mutations within the riboso-
mal proteins L4 and L22 (Vester and Douthwaite, 2001). Single
nucleotide polymorphisms (SNPs) can be the cause for resis-
tance against the synthetic drugs quinolones, sulfonamides, and
trimethoprim (Huovinen et al., 1995; Hooper, 2000; Ruiz, 2003)
and mutations within the rpsL gene, which encodes the riboso-
mal protein S12, can result in a high-level streptomycin resistance
(Nair et al., 1993). A frame shift mutation in the chromosomal
ddl gene, encoding a cytoplasm enzyme d-Ala–d-Ala ligase, can
account for glycopeptides resistance (Casadewall and Courvalin,
1999).
ACQUIRED RESISTANCE
This review deals with the description of acquired resistance
against several classes of antibiotics. For each class the develop-
ment of resistance is summarized along with the mechanisms
of action. Furthermore an extensive summary is given of the
resistance mechanisms and resistance genes involved.
AMINOGLYCOSIDE
History and action mechanism
The aminoglycoside antibiotics initially known as aminoglyco-
sidic aminocyclitols are over 60 years old (Siegenthaler et al., 1986;
Begg and Barclay, 1995). In the early 1940s the ﬁrst amino-
glycoside discovered was streptomycin in Streptomyces griseus
(Schatz andWaksman,1944). Several years later,additional amino-
glycosides were characterized from other Streptomyces species;
neomycin and kanamycin in 1949 and 1957, respectively. Further-
more, in the 1960s gentamicin was recovered from the actino-
mycete Micromonospora purpurea. Because most aminoglycosides
have been isolated from either Streptomyces or Micromonospora
a nomenclature system has been set up based on their source.
Aminoglycosides that are derived frombacteria of the Streptomyces
genus are named with the sufﬁx “-mycin,” while those which are
derived from Micromonospora are named with the sufﬁx “-micin.”
The ﬁrst semi-synthetic derivatives were isolated in the 1970s.
For example netilmicin is a derivative of sisomicin whereas
amikacin is derived from kanamycin (Begg and Barclay, 1995;
Davies and Wright, 1997).
Aminoglycosides are antimicrobials since they inhibit protein
synthesis and/or alter the integrity of bacterial cell membranes
(Vakulenko and Mobashery, 2003). They have a broad antimicro-
bial spectrum. Furthermore, they often act in synergy with other
antibiotics as such it makes them valuable as anti-infectants.
Resistance mechanisms
Several aminoglycoside resistance mechanisms have been recog-
nized; (I)Active efﬂux (Moore et al., 1999;Magnet et al., 2001), (II)
Decreased permeability (Hancock, 1981; Taber et al., 1987), (III)
Ribosome alteration (Poehlsgaard and Douthwaite, 2005), (IV)
Inactivation of the drugs by aminoglycoside-modifying enzymes
(Shaw et al., 1993). Intrinsic mechanisms, i.e., efﬂux pumps and
16S rRNA methylases but also chromosomal mutations can cause
the ﬁrst three resistance properties. In recent years acquired 16S
rRNA methylases appear to have increased in importance (Gali-
mand et al., 2005; Doi and Arakawa, 2007; Table 1). The ﬁrst gene
identiﬁedof aplasmid-mediated typeof aminoglycoside resistance
was armA (Galimand et al., 2003). To date ﬁve additional methy-
lases have been reported, i.e., npmA, rmtA, rmtB, rmtC, and rmtD
(Courvalin, 2008; Doi et al., 2008). Data regarding the 16S rRNA
methylase genes are accumulated and provided at the website:
www.nih.go.jp/niid/16s_database/index.html.
The major encountered aminoglycoside resistance mechanism
is the modiﬁcation of enzymes. These proteins are classiﬁed into
three major classes according to the type of modiﬁcation: AAC
(acetyltransferases),ANT (nucleotidyltransferases or adenyltrans-
ferases), APH (phosphotransferases; Shaw et al., 1993; Wright and
Thompson, 1999; Magnet and Blanchard, 2005; Wright, 2005;
Ramirez and Tolmansky, 2010).Within these classes, an additional
subdivision can be made based on the enzymes different region
speciﬁcities for aminoglycoside modiﬁcations: i.e., there are four
acetyltransferases: AAC(1), AAC(2′), AAC(3), and AAC(6′); ﬁve
nucleotidyltransferases: ANT(2′′), ANT(3′′), ANT(4′), ANT(6),
and ANT(9) and seven phosphotransferases: APH(2′′), APH(3′),
APH(3′′), APH(4), APH(6), APH(7′′), and APH(9). Furthermore,
there also exists a bifunctional enzyme, AAC(6′)–APH(2′′), that
can acetylate and phosphorylate its substrates sequentially (Shaw
et al., 1993;Kotra et al., 2000). Table 1displays the currently known
aminoglycoside resistance genes. The action mechanisms of the
determinants, the variety in gene lengths, accession numbers, and
the distribution are all indicated. As can be deduced from the sec-
ond column of Table 1, inconsistencies arose in the nomenclature
of genes for aminoglycoside-modifying enzymes (Vakulenko and
Mobashery, 2003). In some cases, genes were named according
to the site of modiﬁcation, followed by a number to distinguish
between genes. Using a different nomenclature, for example, the
genes for AAC(6′)-Ia and AAC(3)-Ia are referred to as aacA1 and
aacC1, respectively. The nomenclature proposed by Shaw et al.
(1993), who utilize the identical names for the enzymes and the
corresponding genes, but the names of genes are in lowercase
letters and italicized will be used in this review (see Table 1).
According to this more convenient nomenclature, the genes for
theAAC(6′)-Ia andAAC(3)-Ia enzymes are termed aac(6 ′)-Ia and
aac(3)-Ia, respectively.
β-LACTAM
History and action mechanism
As alreadymentionedbefore, theﬁrst antibiotic discoveredwas aβ-
lactam, i.e., penicillin. The Scottish scientist Alexander Flemming
accidentally noticed the production of a substance with antimi-
crobial properties by the mold Penicillium notatum (Flemming,
1929). Over the last 30 years, many new β-lactam antibiotics have
been developed. By deﬁnition, all β-lactam antibiotics have a β-
lactam nucleus in their molecular structure. The β-lactam antibi-
otic family includes penicillins and derivatives, cephalosporins,
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Table 1 | Acquired Aminoglycoside resistance genes.
Gene name Mechanism Length
(nt)
Accession number
or reference
Coding region Genera
aac(2′)-Ia ACT 537 L06156 264..800 Providencia
aac(2′)-Ib ACT 588 U41471 265..852 Mycobacterium
aac(2′)-Ic ACT 546 U72714 373..918 Mycobacterium
aac(2′)-Id ACT 633 U72743 386..1018 Mycobacterium
aac(2′)-Ie ACT 549 NC_011896 3039059..3039607 Mycobacterium
aac(3)-I ACT 465 AJ877225 5293..5757 Pseudomonas
aac(3)-Ia ACT 534 X15852 1250..1783 Acinetobacter, Escherichia, Klebsiella, Salmonella, Serra-
tia, Streptomyces
aac(3)-Ib ACT 531 L06157 555..1085 Pseudomonas
aac(3)-Ib-aac(6′)-Ib ACT 1,005 AF355189 1435..2439 Pseudomonas
aac(3)-Ic ACT 471 AJ511268 1295..1765 Pseudomonas
aac(3)-Id ACT 477 AB114632 104..580 Proteus, Pseudomonas, Salmonella, Vibrio
aac(3)-Ie ACT 477 AY463797 8583..9059 Proteus, Pseudomonas, Salmonella, Vibrio
aac(3)-If ACT 465 AY884051 61..525 Serratia, Pseudomonas
aac(3)-Ig ACT 477 CP000282 2333620..2334096 Saccharophagus
aac(3)-Ih ACT 459 CP000490 509912..510370 Paracoccus
aac(3)-Ii ACT 459 CP000356 638262..638720 Sphingopyxis
aac(3)-Ij ACT CP000155 Hahella
aac(3)-Ik ACT 444 BX571856 765853..766296 Staphylococcus
aac(3)-IIa ACT 861 X51534 91..951 Acinetobacter, Enterobacter, Escherichia, Klebsiella,
Pseudomonas, Salmonela
aac(3)-IIb ACT 810 M97172 656..1465 Serratia
aac(3)-IIc ACT 861 X54723 819..1679 Escherichia
aac(3)-IId ACT 861 EU022314 1..861 Escherichia
aac(3)-IIe ACT 861 EU022315 1..861 Escherichia
aac(3)-IIIa ACT 816 X55652 1124..1939 Pseudomonas
aac(3)-IIIb ACT 738 L06160 984..1721 Pseudomonas
aac(3)-IIIc ACT 840 L06161 106..945 Pseudomonas
aac(3)-IVa ACT 786 X01385 244..1029 Escherichia
aac(3)-Va
aac(3)-Vb
aac(3)-VIa ACT 900 M88012 193..1092 Enterobacter, Escherichia, Salmonella
aac(3)-VIIa ACT 867 M22999 493..1359 Streptomyces
aac(3)-VIIIa ACT 861 M55426 466..1326 Streptomyces
aac(3)-IXa ACT 846 M55427 274..1119 Micromonospora
aac(3)-Xa ACT 855 AB028210 2711..3565 Streptomyces
aac(6′) ACT 441 AY553333 1392..1832 Pseudomonas
aac ACT 555 AJ628983 1985..2539 Pseudomonas
aac(6′) ACT 402 DQ302723 81..482 Pseudomonas
aac(6′) ACT 555 EU912537 2092..2646 Pseudomonas
aac(6′)-Ia ACT 558 M18967 757..1314 Citrobacter, Escherichia, Klebsiella, Shigella
aac(6′)-Ib ACT 606 M21682 380..985 Klebsiella, Proteus, Pseudomonas
aac(6′)-Ib-cr ACT 519 EF636461 1124..1642 Enterobacter, Escherichia, Klebsiella, Pseudomonas, Sal-
monella
aac(6′)-Ic ACT 441 M94066 1554..1994 Serratia
aac(6′)-Id ACT 450 X12618 905..1354 Klebsiella
aac(6′)-Ie
aac(6′)-If ACT 435 X55353 279..713 Enterobacter
aac(6′)-Ig ACT 438 L09246 544..981 Acinetobacter
aac(6′)-Ih ACT 441 L29044 352..792 Acinetobacter
aac(6′)-Ii ACT 549 L12710 169..717 Enterococcus
(Continued)
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Table 1 | Continued
Gene name Mechanism Length
(nt)
Accession number
or reference
Coding region Genera
aac(6′)-Ij ACT 441 L29045 260..700 Acinetobacter
aac(6′)-Ik ACT 438 L29510 369..806 Acinetobacter
aac(6′)-Il ACT 522 Z54241 530..1051 Acinetobacter, Citrobacter
aac(6′)-Im ACT 537 AF337947 1215..1751 Escherichia
aac(6′)-In ACT 573 Wu et al. (1997) Citrobacter
aac(6′)-Iq ACT 552 AF047556 127..678 Klebsiella, Salmonella
aac(6′)-Ir ACT 441 AF031326 1..441 Acinetobacter
aac(6′)-Is ACT 441 AF031327 1..441 Acinetobacter
aac(6′)-It ACT 441 AF031328 1..441 Acinetobacter
aac(6′)-Iu ACT 441 AF031329 1..441 Acinetobacter
aac(6′)-Iv ACT 441 AF031330 1..441 Acinetobacter
aac(6′)-Iw ACT 441 AF031331 1..441 Acinetobacter
aac(6′)-Ix ACT 441 AF031332 1..441 Acinetobacter
aac(6′)-Iy ACT 438 AF144880 3452..3979 Salmonella
aac(6′)-Iz ACT 462 AF140221 390..851 Stenotrophomonas
aac(6′)-Iaa ACT 438 NC_003197 1707358..1707795 Salmonella
aac(6′)-Iad ACT 435 AB119105 1..435 Acinetobacter
aac(6′)-Iae ACT 552 AB104852 1935..2486 Pseudomonas, Salmonella
aac(6′)-Iaf ACT 552 AB462903 1200..1751 Pseudomonas
aac(6′)-Iai ACT 567 EU886977 544..1110 Pseudomonas
aac(6′)-I30 ACT 555 AY289608 1524..2078 Salmonella
aac(6′)-31 ACT 519 AJ640197 2474..2992 Acinetobacter
aac(6′)-32 ACT 555 EF614235 2247..2801 Pseudomonas
aac(6′)-33 ACT 555 GQ337064 1203..1757 Pseudomonas
aac(6′)-IIa ACT 555 M29695 707..1261 Aeromonas, Klebsiella, Pseudomonas, Salmonella
aac(6′)-IIb ACT 543 L06163 532..1074 Pseudomonas
aac(6′)-IIc ACT 582 AF162771 62..643 Enterobacter, Klebsiella, Pseudomonas
aac(6′)-IId
aac(6′)-III
aac(6′)-IV ACT 435 X55353 279..713 Enterobacter
aac(6′)-aph(2′′) NUT 1,440 M13771 304..1743 Enterococcus, Lactobacillus, Staphylococcus, Streptococ-
cus
aacA29 ACT 381 AY139599 768..1148 Unknown
aacA43 ACT 564 HQ247816 639..1202 Klebsiella
aadA1 NUT 972 X02340 223..1194 Acinetobacter, Aeromonas, Enterobacter, Escherichia,
Klebsiella, Proteus, Pseudomonas, Salmonella, Shigella,
Vibrio
aadA1b NUT 792 M95287 3320..4111 Pseudomonas, Serratia
aadA2 NUT 780 X68227 166..945 Acinetobacter, Aeromonas, Citrobacter, Enterobacter,
Escherichia, Klebsiella, Proteus, Pseudomonas, Salmo-
nella, Shigella, Staphylococcus, Vibrio,Yersinia
aadA3 NUT 792 AF047479 1296..2087 Escherichia
aadA4 NUT 789 Z50802 1306..2094 Acinetobacter, Aeromonas, Escherichia, Pseudomonas,
aadA5 NUT 789 AF137361 64..852 Acinetobacter, Aeromonas, Escherichia, Pseudomonas,
Salmonella, Shigella, Staphylococcus, Vibrio
aadA6 NUT 846 AF140629 61..906 Pseudomonas
aadA7 NUT 798 AF224733 32..829 Escherichia, Salmonella, Vibrio
aadA8 NUT 792 AF326210 1..792 Klebsiella, Vibrio
aadA8b NUT 792 AM040708 1174..1965 Escherichia
aadA9 NUT 837 AJ420072 26773..27609 Corynebacterium
aadA10 NUT 834 U37105 2807..3640 Pseudomonas
(Continued)
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Table 1 | Continued
Gene name Mechanism Length
(nt)
Accession number
or reference
Coding region Genera
aadA11 NUT 846 AY144590 1..846 Pseudomonas, Riemerella
aadA12 NUT 792 AY665771 1..792 Escherichia, Salmonella,Yersinia
aadA13 NUT 798 AY713504 1..798 Escherichia, Pseudomonas,Yersinia
aadA14 NUT 786 AJ884726 540..1325 Pasteurella
aadA15 NUT 792 DQ393783 1800..2591 Pseudomonas
aadA16 NUT 846 EU675686 3197..4042 Escherichia, Klebsiella, Vibrio
aadA17 NUT 792 FJ460181 774..1565 Aeromonas
aadA21 NUT 792 AY171244 47..838 Salmonella
aadA22 NUT 792 AM261837 74..865 Escherichia, Salmonella
aadA23 NUT 780 AJ809407 119..898 Salmonella
aadA24 NUT 780 AM711129 1264..2043 Escherichia, Salmonella
aadC NUT 477 V01282 225..701 Staphylococcus
aadD NUT 771 AF181950 3176..3946 Staphylococcus
ant(2′′)-Ia NUT 543 X04555 1296..1829 Acinetobacter, Enterobacter, Escherichia, Klebsiella, Pro-
teus, Pseudomonas, Salmonella, Serratia, Shigella, Vibrio
ant(3′′)-Ih-aac(6′)-IId NUT-ACT 1,392 AF453998 3555..4946 Serratia
ant(4′)-Ib NUT 771 AJ506108 209..979 Bacillus
ant(4′)-IIa NUT 759 M98270 145..903 Pseudomonas
ant(4′)-IIb NUT 756 AY114142 1061..1816 Pseudomonas
ant(6)-Ia NUT 909 AF330699 22..930 Enterococcus, Staphylococcus
ant(6)-Ib NUT 858 FN594949 27482..28339 Campylobacter
ant(9)-Ia NUT 783 X02588 331..1113 Enterococcus, Staphylococcus
ant(9)-Ib NUT 768 M69221 271..1038 Enterococcus, Staphylococcus
aph(2′′)-Ia
aph(2′′)-Ib PHT 900 AF337947 272..1171 Enterococcus, Escherichia
aph(2′′)-Ic PHT 921 U51479 196..1116 Enterococcus
aph(2′′)-Id PHT 906 AF016483 131..1036 Enterococcus
aph(2′′)-Ie PHT 906 AY743255 131..1036 Enterococcus
aph(3′)-Ia PHT 816 J01839 1162..1977 Escherichia, Klebsiella, Pseudomonas, Salmonella
aph(3′)-Ib PHT 816 M20305 779..1594 Escherichia
aph(3′)-Ic PHT 816 X625115 410..1225 Acinetobacter, Citrobacter, Escherichia, Klebsiella, Salmo-
nella, Serratia,Yersinia
aph(3′)-Id PHT 816 Z48231 820..1635 Escherichia
aph(3′)-IIa PHT 795 X57709 1..795 Escherichia, Pseudomonas, Salmonella
aph(3′)-IIb PHT 807 X90856 388..1194 Pseudomonas
aph(3′)-IIc PHT 813 AM743169 2377498..2378310 Stenotrophomonas
aph(3′)-III PHT 795 M26832 604..1398 Bacillus, Campylobacter, Enterococcus, Staphylococcus,
Streptococcus
aph(3′)-IV PHT 789 X03364 277..1065 Bacillus
aph(3′)-Va PHT 807 K00432 307..1113 Streptomyces
aph(3′)-Vb PHT 792 M22126 373..1164 Streptomyces
aph(3′)-Vc PHT 795 S81599 282..1076 Micromonospora
aph(3′)-Va PHT 780 X07753 103..882 Acinetobacter, Pseudomonas
aph(3′)-VIb PHT 780 AJ627643 4934..5713 Alcaligenes
aph(3′)-VIIa PHT 753 M29953 131..1036 Campylobacter
aph(3′)-VIII PHT 804 AF182845 1..804 Streptomyces
aph(3′)-XV PHT 795 Y18050 4758..5552 Achromobacter, Citrobacter, Pseudomonas
aph(3′′)-Ia PHT 819 M16482 501..1319 Streptomyces
aph(3′′)-Ib PHT 801 AB366441 11310..12110 Enterobacter, Escherichia, Klebsiella, Pasteurella,
Pseudomonas, Salmonella, Shigella,Yersinia, Vibrio
aph(4)-Ia PHT 1,026 V01499 231..1256 Escherichia
(Continued)
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Table 1 | Continued
Gene name Mechanism Length
(nt)
Accession number
or reference
Coding region Genera
aph(4)-Ib PHT 999 X03615 232..1230 Streptomyces
aph(6)-Ia PHT 924 AY971801 1..924 Streptomyces
aph(6)-Ib PHT 924 X05648 382..1305 Streptomyces
aph(6)-Ic PHT 801 X01702 485..1285 Escherichia, Pseudomonas, Salmonella
aph(6)-Id PHT 837 M28829 866..1702 Enterobacter, Escherichia, Klebsiella, Pasteurella,
Pseudomonas, Salmonella, Shigella,Yersinia, Vibrio
aph(7′′)-Ia PHT 999 X03615 232..1230 Streptomyces
aph(9)-Ia PHT 996 U94857 151..1146 Legionella
aph(9)-Ib PHT 993 U70376 7526..8518 Streptomyces
apmA ACT 822 FN806789 2858..3682 Staphylococcus
armA MET 774 AY220558 1978..2751 Acinetobacter, Citrobacter, Enterobacter, Escherichia,
Klebsiella, Salmonella, Serratia
npmA MET 660 AB261016 3069..3728 Escherichia
rmtA MET 756 AB120321 6677..7432 Pseudomonas
rmtB MET 756 AB103506 1410..2165 Enterobacter, Escherichia, Klebsiella, Pseudomonas, Ser-
ratia
rmtC MET 846 AB194779 6903..7748 Proteus, Salmonella
rmtD MET 744 DQ914960 8889..9632 Klebsiella, Pseudomonas
rmtD2 MET 744 HQ401565 14139..14882 Citrobacter, Enterobacter
rmtE MET 822 GU201947 55..876 Escherichia
spc MET 783 X02588 331..1113 Enterococcus, Staphylococcus
sph NUT 801 X64335 6557..7354 Escherichia, Pseudomonas, Salmonella
str NUT 849 X92946 18060..18908 Enterococcus, Staphylococcus, Lactococcus
sat2A ACT 525 X51546 518..1042 Acinetobacter, Enterobacter, Escherichia, Klebsiella, Pro-
teus, Pseudomonas, Salmonella, Shigella, Vibrio
sat3A ACT 543 Z48231 221..763 Escherichia
sat4A ACT 543 X92945 38870..39412 Campylobacter, Enterococcus, Staphylococcus, Strepto-
coccus
This table was adapted from: Elbourne and Hall (2006), Magnet and Blanchard (2005), Partridge et al. (2009), Ramirez and Tolmansky (2010), Shaw et al. (1993),
Vakulenko and Mobashery (2003), and data provided by B. Guerra, B. Aranda, D. Avsaroglu, B. Ruiz del Castillo, and R. Helmuth, on behalf of the Med-Vet Net (EU
Network of Excellence)WP29 Project Group.The data were collected within the subproject “AME’s,” with following participants representing their Institutions: Agnes
Perry Guyomard (ANSES), Dik Mevius (CVI), Yvonne Agerso (DTU), Katie Hopkins (HPA), Silvia Herrera (ISCIII), Alessandra Carattoli (ISS), Antonio Battisti (IZS-Rome),
Stefano Lollai (IZS-Sardegna), Lotte Jacobsen (SSI), Béla Nagy (VMRI), M. Rosario Rodicio and M. C. Mendoza (University of Oviedo, UO), Luis Martínez-Martínez
(University Hospital of Valdecilla, HUV), and Bruno Gonzalez-Zorn (UCM).
ACT, Acetyltransferase; MET, Methyltransferase; NUT, Nucleotidyltransferase; PHT, Phosphotransferase.
AAlthough the sat genes are not aminoglycoside resistance determinants, they encode streptothricin acetyltransferases, for convenience they are included in this
table.
carbapenems, monobactams, and β-lactam inhibitors (Williams,
1987; Bush, 1989; Petri, 2006; Queenan and Bush, 2007).
The core compound of penicillin, 6-aminopenicillanic acid
(6-APA) is used as the main starting point for the prepa-
ration of numerous semi-synthetic derivatives. Although the
cephalosporins are often thought of as new and improved deriv-
atives of penicillin, they were actually discovered as naturally
occurring substances (Petri, 2006). They can be grouped in ﬁrst,
second, third, and forth generation cephalosporins according
to their spectrum of activity and timing of the agent’s intro-
duction. In general, ﬁrst generation agents have good Gram-
positive activity and relatively modest coverage for Gram-negative
organisms; second generation cephalosporins have increased
Gram-negative and somewhat less Gram-positive activity; third
generation antimicrobials have improvedGram-negative and vari-
able Gram-positive activity; forth generation β-lactams have good
true broad spectrum activity against both Gram-negatives and
Gram-positives (Williams, 1987; Marshall et al., 2006). The sec-
ond generation cephamycins are sometimes also grouped among
the cephalosporins.
Because carbapenems diffuse easily in bacteria they are
considered as broad spectrum β-lactam antibiotic. Imipenem
and meropenem are well known representative. Even though
monobactams do not contain a nucleus with a fused ring attached,
they still belong to the β-lactam antibiotics. The β-lactamase
inhibitors, like clavulanic acid, do contain the β-lactam ring,
but they exhibit negligible antimicrobial activity and are used in
combination with β-lactam antibiotics to overcome resistance in
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bacteria that secrete β-lactamase,which otherwise inactivatesmost
penicillins.
The β-lactam antibiotics work by inhibiting the cell wall syn-
thesis by binding to so-called penicillin-binding proteins (PBPs)
in bacteria and interfering with the structural cross linking of pep-
tidoglycans and as such preventing terminal transpeptidation in
the bacterial cell wall. As a consequence it weakens the cell wall
of the bacterium and ﬁnally results in cytolysis or death due to
osmotic pressure (Kotra and Mobashery, 1998; Andes and Craig,
2005).
The β-lactamase inhibitors can be classiﬁed as either reversible
or irreversible and the latter are considered more effective in
that they eventually result in the destruction of enzymatic activ-
ity. Not surprisingly the inhibitors in clinical use, i.e., clavulanic
acid, sulbactam, and tazobactam are all examples of irreversible
β-lactamase inhibitors (Bush, 1988; Drawz and Bonomo, 2010).
Resistance mechanisms
The ﬁrst bacterial enzyme reported to destroy penicillin was an
AmpC β-lactamase of E. coli (Abraham and Chain, 1940). Nowa-
days, bacterial resistance against β-lactam antibiotics is increas-
ing at a signiﬁcant rate and has become a common problem.
There are several mechanisms of antimicrobial resistance to β-
lactam antibiotics. The most common and important mechanism
through which bacteria can become resistant against β-lactams
is by expressing β-lactamases, for example extended-spectrum
β-lactamases (ESBLs), plasmid-mediated AmpC enzymes, and
carbapenem-hydrolyzing β-lactamases (carbapenemases; Brad-
ford, 2001; Jacoby and Munoz-Price, 2005; Paterson and Bonomo,
2005; Poirel et al., 2007; Queenan and Bush, 2007; Jacoby, 2009).
The β-lactamase family has been subdivided either based on
functionality or molecular characteristics. Initially, before genes
were routinely sequenced various biochemical parameters were
determined of the different β-lactamases which allowed classiﬁca-
tion of this AR determinants family into four groups (Bush et al.,
1995; Wright, 2005). Groups 1, 2, and 4 are serine-β-lactamases,
whilemembers of group 3 aremetallo-β-lactamases. Classiﬁcation
based on molecular characteristics, i.e., amino acid homology has
also resulted in four major groups, the so-called Ambler classes
A–D, which correlate well with the functional scheme but lack
details concerning the enzymatic activity. Ambler classes A, C,
and D include the β-lactamases with serine at their active site,
whereas Ambler class B β-lactamases are all metallo-enzymes
who require zinc as a metal cofactor for their catalytic activi-
ties (Ambler, 1980; Bradford, 2001; Paterson and Bonomo, 2005;
Wright, 2005; Poirel et al., 2007, 2010; Bush and Jacoby, 2010;
Drawz andBonomo,2010). In this review theAmbler classiﬁcation
will be used (Table 2).
In addition to the production of β-lactamases resistance can
also be due to possession of altered PBPs. Since β-lactams cannot
bind as effectively to these altered PBPs, the antibiotic is less effec-
tive at disrupting cell wall synthesis. The PBPs are thought to be
the ancestors of the naturally occurring chromosomally mediated
β-lactamase in many bacterial genera (Bradford, 2001).
Although plasmid-encoded penicillinase arose much earlier in
Gram-positives in Staphylococcus aureus, due to the use of peni-
cillin (Aarestrup and Jensen, 1998), the ﬁrst plasmid-mediated
β-lactamase, TEM-1, was described in the early 1960s in Gram-
negatives (Datta and Kontomichalou, 1965). Currently over 1,150
chromosomal, plasmid, and transposon located β-lactamases are
currently known (Bush and Jacoby, 2010; Drawz and Bonomo,
2010; Table 2).
Based on their activity to hydrolyze a small number or a vari-
ety of β-lactams the enzymes can be subdivided into narrow-,
moderate-, broad-, and ESBLs. A commonly used deﬁnition spec-
iﬁes that broad spectrum β-lactamases are capable to provide
resistance to the penicillins and cephalosporins and are not inhib-
ited by inhibitors such as clavulanic acid and tazobactam. The
ESBLs confer resistance to the penicillins, ﬁrst-, second-, and
third-generation cephalosporins and aztreonam, but not to car-
bapenems and are inhibited by β-lactamase inhibitors. In recent
years acquired AR genes encoding ESBLs have become a major
concern (Bradford, 2001). In time the parent enzymes blaTEM-1,
blaTEM-2, and blaSHV-1 have undergone amino acid substitutions
(point mutations) evolving to the ESBLs, starting with blaTEM-3
and blaSHV-2 (Bradford, 2001). Additional mutations at critical
amino acids important for catalysis resulted in over 140 cur-
rently known SHV and TEM ESBL variants. In addition, plasmid-
encoded class C β-lactamases or AmpC determinants, like blaCMY
have also caught people’s awareness (Jacoby, 2009). Furthermore,
in the past decade CTX-M enzymes have become very prevalent
ESBLs, both in nosocomial and in community settings (Cantón
and Coque, 2006).
Table 2 illustrates the size and diversity of the group of β-
lactamases and ESBLs. The vast and still increasing number of
(broad spectrum) β-lactamases and ESBLs has become a problem
for the nomenclature for novel genes. Names have been assigned
according to individual preference rather than according to sys-
tematic procedures (Bush, 1989). Fortunately, an authoritative
website has been constructedon thenomenclature of ESBLshosted
by Jacoby and Bush1.
CHLORAMPHENICOL
History and action mechanism
In 1947, the ﬁrst chloramphenicol, originally referred to as
chloromycetin,was isolated from Streptomyces venezuelae (Ehrlich
et al., 1947). Probably because chloramphenicol is a molecule
with a rather simple structure only a small number of syn-
thetic derivates have been synthesized without adverse effects on
antimicrobial activity (Schwarz et al., 2004). In azidamfenicol two
chlorine atoms (−Cl2) are replaced by an azide group. Substi-
tution of the nitro group (−NO2), by a methyl–sulfonyl residue
(−SO2CH3) resulted in the synthesis of thiamphenicol,whereas in
the ﬂuorinated thiamphenicol derivative ﬂorfenicol the hydroxyl
group (−OH) is replaced with ﬂuorine (−F).
Chloramphenicol is a highly speciﬁc and potent inhibitor
of protein synthesis through its afﬁnity for the peptidyltrans-
ferase of the 50S ribosomal subunit of 70S ribosomes (Schwarz
et al., 2004). Due to its binding to this enzyme the antibiotic
prevents peptide chain elongation. The substrate spectrum of
chloramphenicol includes Gram-positive and Gram-negative, aer-
obic and anaerobic bacteria. Chloramphenicol analogs including
1www.lahey.org/Studies
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Table 2 | β-Lactamases and ESBLs families.
Amber class A
β-lactamases
and ESBLs
Number of
variants*
Amber class B
β-lactamases
and MBLs
Number of
variants*
Amber class C
β-lactamases
and ESBLs
Number of
variants*
Amber class D
β-lactamases
and ESBLs
Number of
variants*
blaACI 1 blaB 13 blaACCa 4 ampH 1
blaAER 1 blaCGB 2 blaACTa 9 ampS 1
blaAST 1 blaDIM 1 blaBIL 1 blaLCR 1
blaBEL 3 blaEBR 1 blaBUT 2 blaNPS 1
blaBES 1 blaGIM 1 blaCFEa 1 blaOXAa 219
blaBIC 1 blaGOB 18 blaCMG 1 loxA 1
blaBPS 5 blaIMPa 30 blaCMYa 72
blaCARB 8 blaINDa 7 blaDHAa 8
blaCKO 5 blaJOHN 1 blaFOXa 10
blaCME 2 blaMUS 1 blaLATa 1
blaCTX-Ma 119 blaNDM 6 blaLENc 24
blaDES 1 blaSPM 1 blaMIRa 5
blaERP 1 blaTUS 1 blaMOR 1
blaFAR 2 blaVIMa 30 blaMOXa 8
blaFONA 6 cepA 7 blaOCH 7
blaGESa,b 17 cﬁA 16 blaOKP-Ac 16
blaHERA 8 cphA 8 blaOKP-Bc 20
blaIMI 3 imiH 1 blaOXYc 23
blaKLUAd 12 imiS 1 blaTRU 1
blaKLUCd 2 blaZEG 1
blaKLUG 1 cepH 1
blaKLUY 4
blaKPCa 11
blaLUT 6
blaMAL 2
blaMOR 1
blaNMC-A 1
blaPERa 7
blaPME 1
blaPSE 4
blaRAHN 2
blaROB 1
blaSED 1
blaSFC 1
blaSFO 1
blaSHVa 141
blaSMEa 3
blaTEMa 187
blaTLA 1
blaTOHO 1
blaVEBa 7
blaZ 1
cdiA 1
cfxA 6
cumA 1
hugA 1
penA 1
*Last update: June 17th, 2011.
aAccording to http://www.lahey.org/Studies.
bGES and IBC-type ESBLs have all been renamed as blaGES according to Weldhagen et al. (2006).
cAccording to http://www.pasteur.fr/ip/easysite/go/03b-00002u-03q/beta-lactamase-enzyme-variants.
dblaKLUA, blaKLUC, blaKLUG, and blaKLUY seem to be the chromosomal progenitors of acquired CTX-M group 2, 1, 8, and 9 genes, respectively (Saladin et al., 2002; Olson
et al., 2005).
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the ﬂuorinated derivative ﬂorfenicol have a similar spectrum of
activity.
Resistance mechanism
The ﬁrst and still most frequently encountered mechanism of bac-
terial resistance to chloramphenicol is enzymatic inactivation by
acetylation of the drug via different types of chloramphenicol
acetyltransferases (CATs; Murray and Shaw, 1997; Schwarz et al.,
2004; Wright, 2005). CATs are able to inactivate chloramphenicol
as well as thiamphenicol and azidamfenicol, however, due to its
structural modiﬁcation ﬂorfenicol is resistant to inactivation by
these enzymes. Consequently, chloramphenicol resistant strains,
in which resistance is exclusively based on the activity of CAT, are
susceptible to ﬂorfenicol. There are two deﬁned types of genes
coding CATs which distinctly differ in their structure: i.e., the clas-
sical catA determinants and the novel, also known as xenobiotic
CATs, encoded by catB variants (Table 3). Besides the inactivat-
ing enzymes, there are also reports on other chloramphenicol
resistance systems, such as inactivation by phosphotransferases,
mutations of the target site, permeability barriers, and efﬂux sys-
tems (Schwarz et al., 2004). Of the latter mechanism, cmlA and
ﬂoR are the most commonly known (Bissonnette et al., 1991;
Briggs and Fratamico, 1999). The presence of a cmlA gene will
result in resistance to chloramphenicol, but susceptibility to ﬂor-
fenicol. In contrast, ﬂoR will give rise to a chloramphenicol and
ﬂorfenicol resistance phenotype. Inconsistencies in the nomen-
clature arose, like with many other AR genes, due to the increas-
ing number of chloramphenicol resistance determinants. Schwarz
et al. (2004) suggested a uniﬁed nomenclature. Table 3 represents
the currently known chloramphenicol/ﬂorfenicol resistance genes.
Some characteristics which are mentioned in Table 3 are mecha-
nism of action, diverse gene lengths, accession numbers, and the
distribution.
GLYCOPEPTIDE
History and action mechanism
In the late 1950s, the ﬁrst glycopeptide, vancomycin was intro-
duced in a clinical setting. Vancomycin was isolated as a fer-
mentation product from a soil bacterium, Streptomyces orien-
talis, displaying antimicrobial activity (McCormick et al., 1956).
Nearly 30 years later followed another glycopeptide antibiotic,
teicoplanin (Parenti et al., 1978). Currently, four groups of gly-
copeptides are recognized, i.e., vancomycin type, avoparcin type,
ristocetin type, and teicoplanin type. (Yao and Crandall, 1994).
Among them, vancomycin and teicoplanin are the only two ther-
apeutics currently used against Gram-positive microorganisms.
During the 1990s, an association between the use of avoparcin and
the occurrence of glycopeptide-resistant enterococci (GRE), more
commonly designated VRE, in farm animals was demonstrated
(Aarestrup, 1995; Klare et al., 1995). As a consequence avoparcin
was banned as a growth promoter in all European Union countries
in 1997.
Glycopeptides have an unusual mode of action. Instead of
inhibiting an enzyme, they bind to a substrate. To be more spe-
ciﬁc, the molecular target of these glycopeptide antibiotics is the
d-alanyl–d-alanine (d-Ala–d-Ala) terminus of the cell wall pep-
tidoglycan precursor. After the glycopeptides are bound to their
target, they inhibit the subsequent transglycosylation reaction by
steric hindrance. (Gao, 2002; Klare et al., 2003).
Resistance mechanism
The introduction of antibiotics into clinical setting is usually fol-
lowed by the fairly rapid emergence of resistant bacteria. In this
respect, vancomycin was somewhat atypical, because for almost
30 years following its introduction, resistance to this glycopep-
tide was reported only rarely and appeared to have little clin-
ical signiﬁcance. However, in the late 1980s, the emergence of
acquired glycopeptides resistance was recognized for the ﬁrst time
(Leclercq et al., 1988; Johnson et al., 1990). This vancomycin resis-
tance resulted from the production of modiﬁed peptidoglycan
precursors ending in d-Ala–d-Lac (VanA, VanB, and VanD) or
d-Ala–d-Ser (VanC, VanE, and VanG), to which glycopeptides
exhibit low binding afﬁnities. Classiﬁcation of glycopeptide resis-
tance is based on the primary sequence of the structural genes
for the resistance-mediating ligases. The vanA and vanB oper-
ons are located on plasmids or on the chromosome, whereas the
vanC1, vanC2/3, vanD, vanE, and vanG have so far been found
exclusively on the chromosome (Gao, 2002; Klare et al., 2003;
Depardieu et al., 2007). Currently, resistance to the glycopeptides,
vancomycin, and teicoplanin or both, has been detected in six, all
Gram-positive bacterial genera: Enterococcus, Erysipelothrix, Lac-
tobacillus,Leuconostoc,Pediococcus, and Staphylococcus (Woodford
et al., 1995).
MACROLIDE–LINCOSAMIDE–STREPTOGRAMIN B
History and action mechanism
The ﬁrst macrolide, erythromycin A, was discovered in the early
1950s (McGuire et al., 1952). The main structural component of
this molecule is a large lactone ring to which amino and/or neutral
sugars are attached by glycosidic bonds. To address the limitations
of erythromycin, like chemical instability, poor absorbance, and
bitter taste, newer 14-, 15-, and 16-membered ring macrolides
such as clarithromycin and the azalide, azithromycin, have been
developed (Kirst, 2002; Roberts, 2002).
Macrolides have a similar mode of antibacterial action
and comparable antibacterial spectra as two other antibiotic
classes, i.e., lincosamides and streptogramins B. Consequently,
these antibiotics, although chemically distinct, have been clus-
tered together asMacrolide–Lincosamide–StreptograminB (MLS)
antibiotics (Roberts, 2002). Nowadays this class of antibiotics
should even be extended due to the development of various syn-
thetic drugs. The ketolides (Zhanel et al., 2002; Ackermann and
Rodloff, 2003) and oxazolidinones (Diekema and Jones, 2000) can
be grouped together with the MLS antimicrobial agents which
results in the MLSKO family of antibiotics (Roberts, 2008).
Macrolides, lincosamides, and streptogramins B all inhibit pro-
tein synthesis by binding to the 50S ribosomal subunit of bacteria
(Weisblum, 1995; Roberts, 2002).
Resistance mechanism
Shortly after the introduction of erythromycin into clinical setting
in the 1950s, bacterial resistance to this antibiotic was reported for
the ﬁrst time in staphylococci (Weisblum, 1995). Since then a large
number of bacteria have been identiﬁed that are resistant to MLS
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Table 3 | Acquired chloramphenicol resistance genes.
Group Gene Gene(s) included Mechanism Length
(nt)
Accession
number
Coding region Genera
Type A-1 catA1 cat, catI, pp-cat Inactivating
enzyme
660 V00622 244..903 Acinetobacter, Escherichia,
Klebsiella, Salmonella, Serratia,
Shigella
Type A-2 catA2 cat, catII Inactivating
enzyme
642 X53796 187..828 Aeromonas, Agrobacterium,
Escherichia, Haemophilus,
Photobacterium, Salmonella
Type A-3 catA3 cat, catIII Inactivating
enzyme
642 X07848 272..913 Actinobacillus, Edwardsiella,
Klebsiella, Mannheimia,
Pasteurella, Shigella
Type A-4 Cat Inactivating
enzyme
654 M11587 880..1533 Proteus
Type A-5 Cat Inactivating
enzyme
663 P20074* 1002758..1003420 Streptomyces
Type A-6 cat86 Inactivating
enzyme
663 K00544 145..807 Bacillus
Type A-7 cat(pC221) cat, catC Inactivating
enzyme
648 X02529 2267..2914 Bacillus, Enterococcus,
Lactobacillus, Staphylococcus,
Streptococcus
Type A-8 cat(pC223) cat Inactivating
enzyme
648 AY355285 1000..1647 Enterococcus, Lactococcus,
Listeria, Staphylococcus,
Streptococcus
Type A-9 cat(pC194) cat, cat-TC Inactivating
enzyme
651 NC_002013 1260..1910 Bacillus, Enterococcus,
Lactobacillus, Staphylococcus,
Streptococcus
Type A-10 Cat Inactivating
enzyme
687 AY238971 1055..1741 Bacillus
Type A-11 catP catD Inactivating
enzyme
624 U15027 2953..3576 Clostridium, Neisseria
Type A-12 catS Inactivating
enzyme
492§ X74948 1..492 Streptococcus
Type A-13 Cat Inactivating
enzyme
624 M35190 309..932 Aeromonas, Campylobacter
Type A-14 Cat Inactivating
enzyme
651 S48276 479..1129 Listonella, Photobacterium,
Proteus
Type A-15 catB Inactivating
enzyme
660 M93113 145..804 Clostridium
Type A-16 catQ Inactivating
enzyme
660 M55620 459..1118 Clostridium, Streptococcus
Type B-1 catB1 cat Inactivating
enzyme
630 M58472 148..777 Agrobacterium
Type B-2 catB2 Inactivating
enzyme
633 AF047479 5957..6589 Acinetobacter, Aeromonas,
Bordetella, Escherichia,
Klebsiella, Pasteurella,
Pseudomonas, Salmonella
Type B-3 catB3 catB4, catB5,
catB6, catB8
Inactivating
enzyme
633 AJ009818 883..1515 Acinetobacter, Aeromonas,
Bordetella, Enterobacter,
Escherichia, Klebsiella,
Kluyvera, Morganella,
Pseudomonas, Salmonella,
Serratia, Shigella
(Continued)
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Table 3 | Continued
Group Gene Gene(s) included Mechanism Length
(nt)
Accession
number
Coding region Genera
Type B-4 catB7 Inactivating
enzyme
639 AF036933 177..815 Pseudomonas
Type B-5 catB9 Inactivating
enzyme
630 AF462019 27..656 Vibrio
Type B-6 catB10 Inactivating
enzyme
633 AF878850 1197..1829 Pseudomonas
Type E-1 cmlA1 cmlA, cmlA2,
cmlA4, cmlA5,
cmlA6, cmlA7,
cmlA8, cmlA10,
cmlB
Efﬂux 1,260 M64556 601..1860 Acinetobacter, Aeromonas,
Arcanobacterium, Entero-
bacter, Escherichia, Klebsiella,
Pseudomonas, Salmonella,
Serratia, Staphylococcus
Type E-2 cml Efﬂux 903 M22614 427..1335 Escherichia
Type E-3 ﬂoR cmlA-like, ﬂo,
pp-ﬂo, cmlA9
Efﬂux 1,215 AF071555 4445..5659 Acinetobacter, Aeromonas,
Bordetella, Pasteurella,
Salmonella,
Stenotrophomonas, Vibrio
Type E-4 fexA Efﬂux 1,428 AJ549214 177..1604 Bacillus, Staphylococcus
Type E-5 cml Efﬂux 1,179 X59968 508..1686 Corynebacterium,
Pseudomonas
Type E-6 cmlv Efﬂux 1,311 U09991 28..1338 Staphylococcus
Type E-7 cmrA cmr Efﬂux 1,176 Z12001 993..2168 Uncultured
Type E-8 cmr cmx Efﬂux 1,176 U85507 3518..4693 Acinetobacter, Escherichia,
Klebsiella, Salmonella,
Serratia, Shigella
cfr Inactivating
enzyme
1,050 AJ579365 6290..7339 Aeromonas, Agrobacterium,
Escherichia, Haemophilus,
Photobacterium, Salmonella
pexA Efﬂux 1,248 HM537013 24055..25302 Actinobacillus, Edwardsiella,
Klebsiella, Mannheimia,
Pasteurella, Shigella
Adapted from Partridge et al. (2009), Schwarz et al. (2004). §Partial sequence. *Protein accession number, nucleotide sequence not available in DNA library.
due to the presence of various different genes. The AR determi-
nants responsible include rRNA methylases, efﬂux, and inactivat-
ing genes (Roberts et al., 1999; Roberts, 2008). The latter group
can be further subdivided in esterases, lyases, phosphorylases, and
transferases (Table 4).
The most common mechanism of MLS resistance is due to the
presence of rRNA methylases, encoded by the erm genes. These
enzymes methylate the adenine residue(s) resulting in MLS resis-
tance. The methylated adenine prevents the binding of the drugs
from binding to the 50S ribosomal subunit. The other two mech-
anisms efﬂux pumps and inactivating genes are encoded by msr
and ere determinants, respectively.
Because currently over 60 MLS resistance genes are recognized
a nomenclature for naming these genes has been proposed that
considers the same rules developed for identifying and naming
new tetracycline resistance genes (see below; Roberts et al., 1999;
Roberts, 2008). Table 4 represents the MLS acquired resistance
genes. The genes included, the resistance mechanism, diverse gene
lengths and accession number, and their distribution are displayed
in this table.
QUINOLONE
History and action mechanism
In 1962, during the process of synthesis and puriﬁcation of chloro-
quine (an antimalarial agent), a quinolone derivative, nalidixic
acid, was discovered which possessed bactericidal activity against
Gram-negatives (Lescher et al., 1962). The second generation
quinolones arose when it became clear that the addition of a
ﬂuoride atom at position 6 of a quinolone molecule, creating
a ﬂuoroquinolone, greatly enhanced its biological activity. Dur-
ing the 1980s, various ﬂuoroquinolones were developed, e.g.,
ciproﬂoxacin, norﬂoxacin, and oﬂoxacin. These ﬂuoroquinolones
demonstrated a broadened antimicrobial spectrum, including
some Gram-positives (Wolfson and Hooper, 1989; Hooper, 2000;
King et al., 2000).
In the 1990s, further alterations resulted in the third-generation
(ﬂuoro)quinolones, e.g., levoﬂoxacin and sparﬂoxacin, showing
potent activity against both Gram-negative and Gram-positive
microbes. The new compounds, such as trovaﬂoxacin, also show
promising activity against anaerobic bacteria (Hooper, 2000; King
et al., 2000).
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Table 4 | Acquired macrolide–lincosamide–streptogramin B (MLS) resistance genes.
Gene Gene(s) included Mechanism Length
(nt)
Accession
number
Coding
region
Genera
car (A) Efﬂux 1,656 M80346 411..2066 Streptomyces
cfr rRNA
methylase
1,050 AM408573 10028..11077 Staphylococcus
cmr Other 1,380 U43535 646..2025 Corynebacterium
ere(A) Inactivating
enzymeA
1,221 AY183453 2730..3950 Citrobacter, Enterobacter, Escherichia, Klebsiella,
Pantoea, Providencia, Pseudomonas, Serratia,
Staphylococcus, Stenotrophomonas, Vibrio
ere(B) Inactivating
enzymeA
1,260 X03988 383..1642 Acinetobacter, Citrobacter, Enterobacter, Escherichia,
Klebsiella, Proteus, Pseudomonas, Staphylococcus
ere(C) Inactivating
enzymeA
1,257 FN396877 943..2199 Klebsiella
erm(A) erm(TR) rRNA
methylase
732 X03216 4551..5282 Aggregatibacter, Bacteroides, Enterococcus,
Helcococcus, Peptostreptococcus, Prevotella,
Staphylococcus, Streptococcus
erm(B) erm(2), erm(AM),
erm(AMR),
erm(BC), erm(BP),
erm(BZ), erm(IP),
erm(P)
rRNA
methylase
738 M36722 714..1451 Aggregatibacter, Acinetobacter, Aerococcus,
Arcanobacterium, Bacillus, Bacteroides, Citrobac-
ter, Corynebacterium, Clostridium, Enterobacter,
Escherichia, Eubacterium, Enterococcus, Fusobac-
terium, Gemella, Haemophilus, Klebsiella, Lactobacil-
lus, Micrococcus, Neisseria, Pantoea, Pediococcus,
Peptostreptococcus, Porphyromonas, Proteus,
Pseudomonas, Ruminococcus, Rothia, Serratia,
Staphylococcus, Streptococcus,Treponema,Wolinella
erm(C) erm(IM), erm(M) rRNA
methylase
735 M19652 988..1722 Aggregatibacter, Actinomyces, Bacillus, Bacteroides,
Corynebacterium, Eubacterium, Enterococcus,
Haemophilus, Lactobacillus, Micrococcus, Neisse-
ria, Prevotella, Peptostreptococcus, Staphylococcus,
Streptococcus,Wolinella
erm(D) erm(J), erm(K) rRNA
methylase
864 M29832 430..1293 Bacillus, Salmonella
erm(E) erm(E2) rRNA
methylase
1,146 X51891 190..1335 Bacteroides, Eubacterium, Fusobacterium,
Ruminococcus, Shigella, Streptomyces
erm(F) erm(FS), erm(FU) rRNA
methylase
801 M14730 241..1041 Aggregatibacter, Actinomyces, Bacteroides, Clostrid-
ium, Corynebacterium, Eubacterium, Enterococcus,
Fusobacterium, Gardnerella, Haemophilus, Lacto-
bacillus, Mobiluncus, Neisseria, Porphyromonas, Pre-
votella, Peptostreptococcus, Ruminococcus, Shigella,
Selenomonas, Staphylococcus, Streptococcus,
Treponema, Veillonella,Wolinella
erm(G) rRNA
methylase
735 M15332 672..1406 Bacillus, Bacteroides, Catenibacterium, Lactobacillus,
Prevotella, Porphyromonas, Staphylococcus
erm(H) car (B) rRNA
methylase
900 M16503 244..1143 Streptomyces
erm(I) mdm(A) rRNA
methylase
– Streptomyces
erm(N) tlr (D) rRNA
methylase
876 X97721 160..1035 Streptomyces
erm(O) lrm, srm(A) rRNA
methylase
783 M74717 40..822 Streptomyces
erm(Q) rRNA
methylase
774 L22689 262..1035 Aggregatibacter, Bacteroides, Clostridium,
Staphylococcus, Streptococcus,Wolinella
(Continued)
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Table 4 | Continued
Gene Gene(s) included Mechanism Length
(nt)
Accession
number
Coding
region
Genera
erm(R) rRNA
methylase
1,023 M11276 333..1355 Arthrobacter
erm(S) erm(SF), tlr (D) rRNA
methylase
960 M19269 460..1419 Streptomyces
erm(T) erm(GT), erm(LF) rRNA
methylase
735 M64090 168..902 Enterococcus, Lactobacillus, Streptococcus
erm(U) lrm(B) rRNA
methylase
837 X62867 361..1197 Streptomyces
erm(V) erm(SV) rRNA
methylase
780 U59450 397..1176 Eubacterium, Fusobacterium, Streptomyces
erm(W) myr (B) rRNA
methylase
936 D14532 1039..1974 Micromonospora
erm(X) erm(CD) erm(Y) rRNA
methylase
855 M36726 296..1150 Arcanobacterium, Biﬁdobacterium, Corynebacterium,
Propionibacterium
erm(Y) erm(GM) rRNA
methylase
735 AB014481 556..1290 Staphylococcus
erm(Z) srm(D) rRNA
methylase
849 AM709783 2817..3665 Streptomyces
erm(30) pikR1 rRNA
methylase
1,011 AF079138 1283..2293 Streptomyces
erm(31) pikR2 rRNA
methylase
969 AF079138 154..1122 Streptomyces
erm(32) tlr (B) rRNA
methylase
843 AJ009971 1790..2632 Streptomyces
erm(33) rRNA
methylase
732 AJ313523 163..894 Staphylococcus
erm(34) rRNA
methylase
846 AY234334 355..1200 Bacillus
erm(35) rRNA
methylase
801 AF319779 33..833 Bacteroides
erm(36) rRNA
methylase
846 AF462611 186..1031 Micrococcus
erm(37) erm(MT) rRNA
methylase
540 AE000516 2229013..
2229552
Mycobacterium
erm(38) rRNA
methylase
1,161 AY154657 63..1223 Mycobacterium
erm(39) rRNA
methylase
741 AY487229 2153..2893 Mycobacterium
erm(40) rRNA
methylase
756 AY570506 2035..2790 Mycobacterium
erm(41) rRNA
methylase
522 EU590124 258..779 Mycobacterium
erm(42) erm(MI) rRNA
methylase
906 FR734406 1..906 Pasteurella, Photobacterium
lmr (A) Efﬂux 1,446 X59926 318..1763 Streptomyces
lnu(A) lin(A) Inactivating
enzymeC
486 M14039 413..898 Clostridium, Lactobacillus, Staphylococcus
lnu(B) lin(B) Inactivating
enzymeC
804 AJ238249 127..930 Clostridium, Enterococcus, Staphylococcus,
Streptococcus
lnu(C) Inactivating
enzymeC
495 AY928180 1150..1644 Streptococcus
(Continued)
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Table 4 | Continued
Gene Gene(s) included Mechanism Length
(nt)
Accession
number
Coding
region
Genera
lnu(D) Inactivating
enzymeC
495 EF452177 19..513 Streptococcus
lnu(F) lin(F), lin(G) Inactivating
enzymeC
822 EU118119 1030..1851 Escherichia, Salmonella
lsa(A) abc-23 Efﬂux 1,497 AY225127 41..1537 Enterococcus
lsa(B) orf3 Efﬂux 1,479 AJ579365 4150..5628 Staphylococcus
lsa(C) Efﬂux 1,479 HM990671 5193..6671 Gardnerella, Streptococcus
mdf (A) Other 1,233 Y08743 1..1233 Escherichia, Shigella
mdt (A) Other 1,257 X92946 10534..11790 Lactococcus
mef (A) Efﬂux 1,218 U70055 314..1531 Acinetobacter, Bacteroides, Citrobacter, Clostrid-
ium, Corynebacterium, Enterococcus, Enterobacter,
Escherichia, Fusobacterium, Gemella, Klebsiella,
Lactobacillus, Micrococcus, Morganella, Neis-
seria, Pantoea, Providencia, Proteus, Ralstonia,
Pseudomonas, Salmonella, Serratia, Staphylococcus,
Streptococcus, Stenotrophomonas
mef (B) Efﬂux 1,230 FJ196385 11084..12313 Escherichia
mef (E) Efﬂux 1,218 U83667 1..1218 Enterococcus, Fusobacterium, Gemella,
Granulicatella, Staphylococcus, Streptococcus
mef (G) Efﬂux 1,218 DQ445270 1..1218 Streptococcus
mph(A) mph(K) Inactivating
enzymeD
906 D16251 1626..2531 Aeromonas, Escherichia, Citrobacter, Enterobacter,
Klebsiella, Pantoea, Pseudomonas, Proteus, Serratia,
Shigella, Stenotrophomonas
mph(B) mph(B) Inactivating
enzymeD
909 D85892 1159..2067 Escherichia, Enterobacter, Proteus, Pseudomonas
mph(C) mph(BM) Inactivating
enzymeD
900 AF167161 5665..6564 Staphylococcus, Stenotrophomonas
mph(D) Inactivating
enzymeD
840§ AB048591 1..840 Escherichia, Klebsiella, Pantoea, Proteus,
Pseudomonas, Stenotrophomonas
mph(E) mph, mph1, mph2 Inactivating
enzymeD
884 AY522431
AF550415
DQ839391
22181..23064 Citrobacter, Escherichia
mre(A) Efﬂux 936 U92073 119..1054 Streptococcus
msr (A) msr (B), msr (SA) Efﬂux 1,467 X52085 343..1809 Corynebacterium, Enterobacter, Enterococ-
cus, Gemella, Pseudomonas, Staphylococcus,
Streptococcus
msr (C) Efﬂux 1,479 AY004350 496..1974 Enterococcus
msr (D) mel, orf5 Efﬂux 1,464 AF274302 2462..3925 Acinetobacter, Bacteroides, Citrobacter, Clostrid-
ium, Corynebacterium, Enterococcus, Enter-
obacter, Escherichia, Gemella, Fusobacterium,
Klebsiella, Morganella, Neisseria, Proteus, Provi-
dencia, Pseudomonas, Ralstonia, Staphylococcus,
Streptococcus, Serratia, Stenotrophomonas
msr (E) mel Efﬂux 1,476 AY522431 20650..22125 Citrobacter, Escherichia
ole(B) Efﬂux 1,710 L36601 1421..3130 Streptomyces
ole(C) Efﬂux 978 L06249 1528..2505 Streptomyces
srm(B) Efﬂux 1,653 X63451 558..2210 Streptomyces
tlc(C) Efﬂux 1,647 M57437 277..1923 Streptomyces
vat (A) Inactivating
enzymeC
660 L07778 258..917 Staphylococcus
(Continued)
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Table 4 | Continued
Gene Gene(s) included Mechanism Length
(nt)
Accession
number
Coding
region
Genera
vat (B) Inactivating
enzymeC
639 U19459 67..705 Enterococcus, Staphylococcus
vat (C) Inactivating
enzymeC
639 AF015628 1307..1945 Staphylococcus
vat (D) sat (A) Inactivating
enzymeC
630 L12033 162..791 Enterococcus
vat (E) sat (G), vat (E-3)–
vat (E-8)
Inactivating
enzymeC
645 AF139725 63..707 Enterococcus, Lactobacillus
vat (F) Inactivating
enzymeC
666 AF170730 70..735 Yersinia
vat (G) Inactivating
enzymeC
651 GQ205627 3037..3687 Enterococcus
vga(A) vga Efﬂux 1,569 M90056 909..2477 Staphylococcus
vga(A)LC vga Efﬂux 1,569 DQ823382 1..1569 Staphylococcus
vga(B) Efﬂux 1,659 U82085 629..2287 Enterococcus, Staphylococcus
vga(C) vga(D) Efﬂux 1,578 GQ205627 1394..2971 Enterococcus
vgb(A) vgb Inactivating
enzymeB
900 M20129 641..1540 Enterococcus, Staphylococcus
vgb(B) Inactivating
enzymeB
888 AF015628 399..1286 Staphylococcus
Adapted from http://faculty.washington.edu/marilynr/. §Partial sequence. AEsterase, BLyase, CTransferase, DPhosphorylase.
Quinolones inhibit the action of DNA gyrase and topoiso-
merase IV, two enzymes essential for bacterial DNA replication
and as a result the microbes are killed. (Hooper, 1995, 2000). DNA
gyrase is a tetrameric enzyme composed of 2GyrA and 2GyrB sub-
units. The topoisomerase IV has a similar structure, comprised of
2 A and 2 B subunits, encoded by parC and parE, respectively. The
four genes coding for the subunits of these enzymes are the targets
for resistance mutations (see below).
Resistance mechanism
For decades, the mechanisms of resistance to quinolones were
believed to be only chromosome-encoded, however, recently three
plasmid-mediated resistance mechanisms have been reported
(Robicsek et al., 2006a; Courvalin, 2008; Martínez-Martínez et al.,
2008). The chromosome-encoded resistance result in either a
decreased outer-membrane permeability related to porin loss, to
the (over)expression of naturally occurring efﬂux pumps or muta-
tions of the molecular targets DNA gyrase and topoisomerase IV
(Hooper, 2000; Ruiz, 2003; Jacoby, 2005). In the latter case muta-
tions occur at speciﬁc “quinolone resistance determining regions”
(QRDR) in the genes gyrA, gyrB, parC, and parE encoding the
subunits of DNA gyrase and topoisomerase IV. Not surprisingly
this QRDR is situated on the DNA-binding surface of the enzymes
(Jacoby, 2005).
Although the possibility of the existence of plasmid-mediated
resistance was already suggested in 1990 (Courvalin, 1990), the
ﬁrst actually identiﬁed plasmid-mediated quinolone resistance
gene, a qnr determinant, which encodes for a protein that pro-
tects DNA gyrase and type IV topoisomerase from quinolone
inhibition, was reported nearly a decade later (Martínez-Martínez
et al., 1998).
Currently ﬁve families of qnr genes have been reported; qnrA
(7), qnrB (39), qnrC (1), qnrD (1), and qnrS (4). The number
in between brackets indicates the variants known of each type
(Jacoby et al., 2008; Cattoir and Nordmann, 2009; Cavaco et al.,
2009; Strahilevitz et al., 2009; Torpdahl et al., 2009). Because of
the increasing number of qnr genes a database has been con-
structed and will be maintained to assign further allele numbers
to novel variants2. Very recently an additional family has been
described, qnrAS in the ﬁsh pathogen Aliivibrio salmonicida (Sun
et al., 2010). Table 5 describes all known qnr families and their
variants, together with the gene lengths, accession numbers, and
in which bacterial genera they have been identiﬁed so far.
The second type of plasmid located quinolone resistant gene is
a cr variant of aac(6 ′)-Ib, aac(6 ′)-Ib-cr, responsible for low-level
ciproﬂoxacin resistance. It encodes an aminoglycoside acetyltrans-
ferase, called AAC(6′)-Ib-cr which has two amino acid changes,
Trp102Arg andAsp179Tyr. These substitutions are responsible for
the enzyme’s ability to acetylate ciproﬂoxacin (Park et al., 2006;
Robicsek et al., 2006b; Strahilevitz et al., 2009).
The third mechanism is qepA, a plasmid-mediated efﬂux
pump which can extrude hydrophilic ﬂuoroquinolones, e.g.,
ciproﬂoxacin and enroﬂoxacin (Périchon et al., 2007;Yamane et al.,
2007). A variant of this resistance pump, QepA2, was identiﬁed in
an E. coli isolate from France (Cattoir et al., 2008).
2www.lahey.org/qnrstudies
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Table 5 | Acquired quinolone resistance genes.
Gene* Length (nt) Accession number Coding region Genera
qepA 1,536 AB263754 7052..8587 Escherichia
qepA2 1,536 EU847537 1672..3207 Escherichia
qnrA1 657 AY070235 303..959 Citrobacter, Enterobacter, Escherichia, Klebsiella, Shigella
qnrA2 657 AY675584 1..657 Klebsiella, Shewanella
qnrA3 657 DQ058661 1..657 Shewanella
qnrA4 657 DQ058662 1..657 Shewanella
qnrA5 657 DQ058663 1..657 Shewanella
qnrA6 657 DQ151889 1..657 Proteus
qnrA7 657 GQ463707 1..657 Shewanella
qnrAS 657 FM178379 1699484..1700140 Aliivibrio
qnrB1 645 DQ351241 37..681 Enterobacter, Escherichia, Klebsiella
qnrB2 645 DQ351242 1..645 Citrobacter, Enterobacter„ Klebsiella, Salmonella
qnrB3 645 DQ303920 37..681 Escherichia
qnrB4 645 DQ303921 4..648 Citrobacter, Enterobacter, Escherichia, Klebsiella
qnrB5 645 DQ303919 37..681 Enterobacter, Salmonella
qnrB6 645 EF520349 37..681 Enterobacter, Escherichia, Klebsiella, Pantoea
qnrB7 645 EU043311 1..645 Enterobacter, Klebsiella
qnrB8 645 EU043312 1..645 Citrobacter, Enterobacter
qnrB9 645 EF526508 1..645 Citrobacter
qnrB10 645 DQ631414 37..681 Citrobacter, Enterobacter, Escherichia, Klebsiella
qnrB11 645 EF653270 4..648 Citrobacter
qnrB12 645 AM774474 2435..3079 Citrobacter
qnrB13 645 EU273756 37..681 Citrobacter
qnrB14 645 EU273757 37..681 Citrobacter
qnrB15 645 EU302865 37..681 Citrobacter
qnrB16 645 EU136183 37..681 Citrobacter
qnrB17 645 AM919398 37..681 Citrobacter
qnrB18 645 AM919399 37..681 Citrobacter
qnrB19 645 EU432277 1..645 Escherichia, Klebsiella, Salmonella
qnrB20 645 AB379831 37..681 Escherichia, Klebsiella
qnrB21 645 FJ611948 1..645 Escherichia
qnrB22 645 FJ981621 37..681 Citrobacter
qnrB23 645 FJ981622 37..681 Citrobacter
qnrB24 645 HM192542 37..681 Citrobacter
qnrB25 645 HQ172108 1..645 Citrobacter
qnrB26 645 HM439644 1..645 Citrobacter
qnrB27 645 HM439641 1..645 Citrobacter
qnrB28 645 HM439643 1..645 Citrobacter
qnrB29 645 HM439649 37..681 Citrobacter
qnrB30 645 HM439650 37..681 Citrobacter
qnrB31 645 HQ418999 1..681 Klebsiella
qnrB32– qnrB39 not public yet
qnrC 666 EU917444 1717..2382 Proteus
qnrD 645 EU692908 1..645 Salmonella
qnrS1 657 AB187515 9737..10393 Enterobacter, Escherichia, Klebsiella, Proteus, Salmonella,
Shigella
qnrS2 657 DQ485530 1..657 Aeromonas, Salmonella
qnrS3 657 EU077611 1..656 Escherichia
qnrS4 657 FJ418153 1..657 Salmonella
*Last update: June 17th 2011.
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STREPTOTHRICIN
History and action mechanism
In the early days of the antibiotics era screening for new com-
pound resulted in thediscovery of a Streptomyces lavendulae isolate
which inhibited growth of Gram-negative as well as Gram-positive
bacteria. Isolation of the active antimicrobial substance resulted
in the identiﬁcation of streptothricin (Waksman and Woodruff,
1942). Delayed toxicity prevents streptothricin’s use in man, but it
is effective in preventing animal infections.
Streptothricins consist of three moieties: gulosamine, strepto-
lidin, and a β-lysine peptide chain. Since, the discovery of the
streptothricin, six analogs have been reported, streptothricin A–
F. The analogs differ from the parent molecule in the number of
β-lysine residues (Keeratipibul et al., 1983; Tschäpe et al., 1984).
The streptothricins are potent inhibitors of bacterial protein
synthesis, via direct binding to ribosomes. They also cause mis-
reading of mRNA codons, although they are unrelated to other
drugs that cause translational ambiguity, like the aminoglycosides
(Tschäpe et al., 1984).
Resistance mechanism
Since streptothricin is inactivated by acetylation in its producer it is
not surprising that the identiﬁed resistancemechanisms are acetyl-
transferases. The ﬁrst streptothricin resistant bacterium identiﬁed
was anE. coli isolate from a rectal swab of pigs under streptothricin
F treatment. The AR gene was localized on a transferable plas-
mid (Tschäpe et al., 1984). Currently three different streptothricin
acetyltransferases are recognized, sat2–sat4 (Partridge and Hall,
2005; see Table 1).
SULFONAMIDE
History and action mechanism
Sulfonamides belong to the oldest introduced synthetic drugs.
They were ﬁrst used in 1932 (Domagk, 1935; Sköld, 2001).
A number of different sulfonamides have been developed of
which the most commonly used nowadays is sulfamethoxazole.
Moreover, since 1968, the combination of trimethoprim and
sulfamethoxazole (called co-trimoxazole) has been used exten-
sively because a combination of both drugs at certain concen-
trations has a synergetic bactericidal effect, it reduces selection
of AR to either drug and associated costs (Roberts, 2002; Grape,
2006).
A sulfonamide, with its structural analogy to p-aminobenzoic
acid, which is involved in the biosynthetic pathway leading to folic
acid, competitively inhibits the enzyme dihydropteroate synthase
(DHPS). This protein is part of the next to last step of the folate
biosynthetic pathway that is required for thymine production and
bacterial cell growth (Sköld, 2000, 2001; Roberts, 2002).
Resistance mechanism
Resistance to sulfonamide among pathogenic bacteria appeared
quite soon after its introduction into clinical practice in the
1930s (Sköld, 2001). Since sulfonamides are synthetic antibacter-
ial agents, naturally occurring enzymes degrading, or modifying
this drug were not to be expected. However, chromosomal sulfon-
amide resistance occurs, mostly low level, by mutations in the folP
gene encoding DHPS (Huovinen et al., 1995; Sköld, 2000, 2001;
Grape, 2006).
Acquired sulfonamide resistance was discovered in the 1960s,
but the plasmid-mediated genes were characterized later on in
the 1980s as sul1 and sul2 (Swedberg and Sköld, 1983; Rådström
and Swedberg, 1988; Sundström et al., 1988). Currently three
plasmid-borne drug-resistant variants of the DHPS enzymes are
known; besides the two genes mentioned above also sul3 has been
identiﬁed (Perreten and Boerlin, 2003).
TETRACYCLINE
History and action mechanism
The ﬁrst tetracycline antibiotic was characterized in 1948 as
chlortetracycline from Streptomyces aureofaciens (Chopra et al.,
1992; Chopra and Roberts, 2001). In consecutive decades addi-
tional tetracyclines were identiﬁed either as naturally occurring
molecules mostly in Streptomyces species (e.g., oxytetracycline,
tetracycline) or products of semi-synthetic approaches (e.g., doxy-
cycline, minocycline; Chopra et al., 1992; Hunter and Hill, 1997;
Chopra and Roberts, 2001).
Tetracyclines were the ﬁrst major group to which the term
“broad spectrum” was applied (Chopra and Roberts, 2001).
Because of this spectrum of activity, their relative safety, and low
cost, tetracyclines have been used widely throughout the world
and are second after penicillin in world consumption. This class
of antibiotic can be separated into two groups, typical, (e.g.,
chlortetracycline, doxycycline, minocycline, oxytetracycline, and
tetracycline) and atypical tetracyclines (e.g., anhydrotetracycline
and 6-thiatetracycline), see below (Rasmussen et al., 1991; Oliva
and Chopra, 1992; Chopra and Roberts, 2001).
Initially, it was thought that tetracyclines andmost of its deriva-
tives are antimicrobial agents only because they inhibit the growth
of microbes by entering the bacterial cell, interactingwith the ribo-
somes, and consequently blocking protein synthesis, the so-called
typical tetracyclines (Speer et al., 1992; Roberts, 2002). However,
Oliva and Chopra (1992) suggested an additional mode of action.
Certain tetracycline derivatives are poor inhibitors of protein syn-
thesis and appear to bind ribosomes inefﬁciently or not at all, in
stead they interact with the bacterial membrane (Rasmussen et al.,
1991; Chopra, 1994).
Resistance mechanism
Prior to themid-1950s, themajority of commensals andpathogens
were susceptible to tetracycline. However, in 1953 the ﬁrst tetra-
cycline resistant bacteria were isolated (Watanabe, 1963). The
resistance mechanisms for the tetracycline class of antibiotics fall
in three categories; energy-dependent efﬂux pumps, ribosomal
protection proteins (RPPs), or enzymatic inactivation.
A novel tetracycline resistance determinant is identiﬁed as
unique if it shares <79% amino sequence identity with all previ-
ously described genes. Initially, letters of the Roman alphabet have
been used to name tetracycline resistance determinants. However,
the number of tet genes has reached the end of the alphabet and to
accommodate new genes, a nomenclature employing numerals for
future determinants was introduced (Levy et al., 1999). Moreover,
also naturally occurring hybrid tetracycline resistance genes exist.
A simple, descriptive nomenclature for these mosaic tet determi-
nants has been proposed incorporating the designations of the
known tet genes classes forming the hybrid, e.g., tet (O/W) and
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tet (O/W/O; Levy et al., 2005; Stanton et al., 2005; van Hoek et al.,
2008).
There are currently over 40 different acquired tetracycline resis-
tance determinants recognized, i.e., 38 tet (tetracycline resistance)
and 3 otr (oxytetracycline resistance) genes, additionally 1 tcr gene
has been identiﬁed (Roberts, 1996, 2005; Brown et al., 2008; see
Table 6). Among these 25 of the tet, 2 of the otr genes and the
only tcr determinant code for efﬂux pumps, whereas 10 tet and
1 otr code for a RPP. The enzymatic inactivation mechanism can
be attributed to 3 tet genes. The tet (U) determinant represents
an unknown tetracycline resistance mechanism since its sequence
does not appear to be related to either efﬂux or RPPs, nor to
the inactivation enzymes (Table 6). The efﬂux and RPP encoding
genes are found in members of Gram-positive, Gram-negative,
aerobic, as well as anaerobic bacterial species. In contrast the enzy-
matic tetracycline inactivation mechanism has so far only been
identiﬁed in Gram-negatives (Table 6). The tet (M) has the broad-
est host range of all tetracycline resistance genes, whereas tet (B)
gene has the widest range among the Gram-negative microbes.
In recent years published data indicate that there are increasing
numbers of Gram-negative bacteria that carry “Gram-positive tet
genes” (Roberts, 2002).
TRIMETHOPRIM
History and action mechanism
Trimethoprim has been available since 1962 and is considered the
last truly new antibacterial agent introduced into clinical prac-
tice (Roth et al., 1962). All later developed agents have been
variations of older antibiotics, that is, belonging to families of
agents, within which cross-resistance is common (Sköld, 2001;
Roberts, 2002). Trimethoprim is a completely synthetic drug,
belonging to the diaminopyrimidine group of compounds, i.e.,
5-benzyl-2,4-diamino-pyrimidine (Huovinen, 1987).
Trimethoprim inhibits the enzyme dihydrofolate reductase
(DHFR) by competitively binding to its active site. DHFR cataly-
sis the NAHPH-dependent reduction of dihydrofolate acid to the
active co-enzyme tetrahydrofolate. As such trimethoprim can be
regarded as an antifolate, a structural analog of folic acid. DHFR,
like DHPS is part of the folate biosynthetic pathway (Sköld, 2001;
Grape, 2006; see section Sulfonamides).
Resistance mechanism
Because trimethoprim like sulfonamide is a synthetic antibacterial
agent, naturally occurring enzymes degrading, or modifying it are
unlikely. However, resistance, mostly low level, can for example
occur via non-allelic and drug-resistant variants of the chromo-
somal folA gene encoding the bacterial DHFR (Huovinen et al.,
1995; Sköld, 2001; Grape, 2006).
High-level resistance is generally achieved by a bypass mecha-
nism through the action of an acquired gene which is a non-allelic
and drug-insusceptible variant of a chromosomal DHFR. These
plasmid-mediated DHFRs emerged in Gram-negative bacteria
within several years of the clinical introduction of the drug (Flem-
ing et al., 1972; Huovinen and Toivanen, 1980; Amyes and Towner,
1990).
Initially, the acquired DHFRs fell into two quite distinct fam-
ilies, dfrA and dfrB genes (Howell, 2005). Members of the dfrA
group are at least 474 nucleotides (nt) long (157 amino acids,
aa), whereas the dfrB genes are 237 nt in length (78 aa). Cur-
rently six plasmid-mediated families can be distinguished with
relatively few dfr determinants originating from Gram-positive
bacteria. (Table 7). The dfrK gene is the newest addition to the
trimethoprim resistance determinant family (Kadlec and Schwarz,
2009). In contrast to the latest reported DHFRs, the oldest fami-
lies, dfrA and dfrB, each contain several members (Roberts, 2002;
Levings et al., 2006). For example, the dfrA group accommodates
over 30 genes. Determinant dfrA27 is the newest reported DHFR
gene among Gram-negatives (Wei et al., 2009), although a newer,
however unpublished, dfrA variant is present in the public DNA
library and some genes apparently have changed nomenclature
(Table 7).Among this family two sub-families canbe distinguished
(Adrian et al., 2000). The dfrA1-group with 12 different genes
share 64–90% identity on amino acids level. The dfrA12-group,
with ﬁve members, display 84% amino acid identity and similar
trimethoprim-inhibition proﬁles. The additional dfrA genes are
less related to each other, some have even less than 25% amino acid
sequence identity. In contrast to the dfrA family, the dfrB group is
somewhat smaller, with only eight reported genes (Levings et al.,
2006; Partridge et al., 2009).
MOBILE GENETIC ELEMENTS
Acquired AR genes are frequently contained within mobile DNA
which can be loosely deﬁned as any segment of DNA that is capa-
ble of translocation from one part of a genome to another or
between genomes. This deﬁnition includes a wide range of distinct
mobile elements. The major players in HGT are the conjugative
and mobilizable elements, the former contain all the genetic infor-
mation required to transfer from one bacterium to another whilst
the latter use the conjugation functions of co-resident conjuga-
tive elements (conjugative plasmids or conjugative transposons)
to transfer to another host. Bacteriophages also play a role in the
spread of DNA between bacteria, they do this by a process called
transduction in which bacterial DNA, rather than phage DNA,
is packaged into the phage head and injected into the recipient
bacterium. There are also elements which are capable of translo-
cation to new sites in the genome but are not themselves capable
of transfer to a new host (of course if they transpose to a conjuga-
tive element they can be moved to new hosts). These include the
transposons and the mobile introns.
Bacteria can also acquire AR genes by transformation. The
process occurs in both Gram-positive and Gram-negative bacte-
ria. Bacteria capable of taking up DNA from the environment are
termed “competent.” Some microorganisms, such as many strep-
tococci, are competent at a speciﬁc stage in their growth whilst
others have no obvious competence window. Some bacteria have
speciﬁc sequence requirements to successfully take up DNA such
as Neisseria (Smith et al., 1999), while others like Bacillus sub-
tilis have no obvious such requirements. In this process naked
DNA is taken up by the recipient bacteria and either incorpo-
rated into the host genome by homologous recombination or
transposition. Alternatively the DNA molecule may be able to
replicate autonomously, e.g., plasmids. Mobile genetic elements
are often acquired by transformation as well as by conjugation. For
a recent review of the mechanisms of transformation see (Kovács
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Table 6 | Acquired tetracycline resistance genes.
Gene Mechanism Length
(nt)
Accession
number
Coding
region
Genera
otr (A) Ribosomal
protection
1,992 X53401 349..2340 Mycobacterium, Streptomyces
otr (B) Efﬂux 1,692 AF079900 40..1731 Mycobacterium, Streptomyces
otr (C) Efﬂux 1,056 AY509111 324..1379 Streptomyces
tcr Efﬂux 1,539 D38215 516..2054 Streptomyces
tet (A) Efﬂux 1,200 X00006 1328..2527 Acinetobacter, Aeromonas, Bordetella, Chryseobacterium, Citrobacter,
Edwardsiella, Enterobacter, Escherichia, Flavobacterium, Klebsiella, Larib-
acter, Plesiomonas, Proteus, Pseudomonas, Salmonella, Serratia, Shigella,
Variovorax, Veillonella, Vibrio
tetA(P) Efﬂux 1,263 L20800 1063..2325 Clostridium
tet (B) Efﬂux 1,206 J01830 1608..2813 Acinetobacter, Actinobacillus, Aeromonas, Aggregatibacter, Brevundimonas,
Citrobacter, Enterobacter, Erwinia, Escherichia, Haemophilus, Klebsiella,
Mannheimia, Moraxella, Neisseria, Pantoea, Pasteurella, Photobacterium,
Plesiomonas, Proteus, Providencia, Pseudomonas, Roseobacter, Salmonella,
Serratia, Shigella,Treponema, Vibrio,Yersinia
tetB(P) Ribosomal
protection
1,959 L20800 2309..4267 Clostridium
tet (C) Efﬂux 1,191 X01654 86..1276 Aeromonas, Bordetella, Chlamydia, Citrobacter, Enterobacter, Escherichia,
Francisella, Halomonas, Klebsiella, Proteus, Pseudomonas, Roseobacter,
Salmonella, Serratia, Shigella, Vibrio
tet (D) Efﬂux 1,185 X65876 1521..2705 Aeromonas, Alteromonas, Citrobacter, Edwardsiella, Enterobacter,
Escherichia, Halomonas, Klebsiella, Morganella, Pasteurella, Photobacterium,
Proteus, Salmonella, Shewanella, Shigella, Vibrio,Yersinia
tet (E) Efﬂux 1,218 L06940 21..1238 Aeromonas, Alcaligenes, Escherichia, Flavobacterium, Plesiomonas, Proteus,
Providencia, Pseudomonas, Roseobacter, Serratia, Vibrio
tet (G) Efﬂux 1,128 AF071555 6644..7771 Acinetobacter, Brevundimonas, Escherichia, Fusobacterium, Mannheimia,
Ochrobactrum, Pasteurella, Proteus, Providencia, Pseudomonas, Roseobacter,
Salmonella, Shewanella, Vibrio
tet (H) Efﬂux 1,203 U00792 716..1918 Acinetobacter, Actinobacillus, Mannheimia, Moraxella, Pasteurella
tet (J) Efﬂux 1,197 AF038993 1084..2280 Escherichia, Morganella, Proteus
tet (K) Efﬂux 1,380 M16217 305..1684 Bacillus, Clostridium, Enterococcus, Eubacterium, Haemophilus, Lacto-
bacillus, Listeria, Mycobacterium, Nocardia, Nocardia, Peptostreptococcus,
Staphylococcus, Streptococcus, Streptomyces
tet (L) Efﬂux 1,377 D00006 189..1565 Acinetobacter, Actinobacillus, Actinomyces, Bacillus, Biﬁdobacterium,
Citrobacter, Clostridium, Enterobacter, Enterococcus, Escherichia, Flavobac-
terium, Fusobacterium, Geobacillus, Kurthia, Lactobacillus, Listeria,
Mannheimia, Morganella, Mycobacterium, Nocardia, Ochrobactrum,
Oceanobacillus, Paenibacillus, Pasteurella, Pediococcus, Peptostreptococcus,
Proteus, Pseudomonas, Rahnella, Salmonella, Sporosarcina, Staphylococcus,
Streptococcus, Streptomyces, Variovorax, Veillonella, Virgibacillus
tet (M) Ribosomal
protection
1,920 U08812 1981..3900 Abiotrophia, Acinetobacter, Actinomyces, Aerococcus, Aeromonas, Aﬁpia,
Arthrobacter, Bacillus, Bacterionema, Bacteroides, Biﬁdobacterium, Brachy-
bacterium, Catenibacterium, Clostridium, Corynebacterium, Edwardsiella,
Eikenella, Enterobacter, Enterococcus, Erysipelothrix, Escherichia, Eubac-
terium, Flavobacterium, Fusobacterium, Gardnerella, Gemella, Granulicatella,
Haemophilus, Kingella, Klebsiella, Kurthia, Lactobacillus, Lactococcus, Lis-
teria, Microbacterium, Mycoplasma, Neisseria, Paenibacillus, Pantoea,
Pasteurella, Peptostreptococcus, Photobacterium, Prevotella, Pseudoal-
teromonas, Pseudomonas, Ralstonia, Selenomonas, Serratia, Shewanella,
Staphylococcus, Streptococcus, Streptomyces, Ureaplasma, Veillonella, Vibrio
(Continued)
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Table 6 | Continued
Gene Mechanism Length
(nt)
Accession
number
Coding
region
Genera
tet (O) Ribosomal
protection
1,920 M18896 207..2126 Actinobacillus, Aerococcus, Anaerovibrio, Biﬁdobacterium, Butyrivib-
rio, Campylobacter, Clostridium, Enterococcus, Eubacterium, Fusobac-
terium, Gemella, Lactobacillus, Megasphaera, Mobiluncus, Neisseria,
Peptostreptococcus, Psychrobacter, Staphylococcus, Streptococcus
tet (Q) Ribosomal
protection
1,926 Z21523 362..2287 Anaerovibrio, Bacteroides, Capnocytophaga, Clostridium, Eubacterium,
Fusobacterium, Gardnerella, Lactobacillus, Mitsuokella, Mobiluncus, Neis-
seria, Peptostreptococcus, Porphyromonas, Prevotella, Ruminococcus,
Selenomonas, Streptococcus, Subdoligranulum, Veillonella
tet (S) Ribosomal
protection
1,926 L09756 447..2372 Enterococcus, Lactobacillus, Lactococcus, Listeria, Staphylococcus,
Streptococcus, Veillonella
tet (T) Ribosomal
protection
1,956 L42544 478..2433 Lactobacillus, Streptococcus
tet (U) Unknown 318 U01917 413..730 Enterococcus, Staphylococcus, Streptococcus
tet (V) Efﬂux 1,260 AF030344 462..1721 Mycobacterium
tet (W) Ribosomal
protection
1,920 AJ222769 3687..5606 Acidaminococcus, Actinomyces, Arcanobacterium, Bacillus, Bacteroides,
Biﬁdobacterium, Butyrivibrio, Clostridium, Fusobacterium, Lactobacil-
lus, Megasphaera, Mitsuokella, Neisseria, Porphyromonas, Prevotella,
Roseburia, Selenomonas, Staphylococcus, Streptococcus, Streptomyces,
Subdoligranulum, Veillonella
tet (X) Enzymatic 1,167 M37699 586..1752 Bacteroides, Sphingobacterium
tet (Y) Efﬂux 1,176 AF070999 1680..2855 Aeromonas, Escherichia, Photobacterium
tet (Z) Efﬂux 1,155 AF121000 11880..13034 Corynebacterium, Lactobacillus
tet (30) Efﬂux 1,185 AF090987 1130..2314 Agrobacterium
tet (31) Efﬂux 1,233 AJ250203 1651..2883 Aeromonas
tet (32) Ribosomal
protection
1,920 DQ647324 181..2100 Enterococcus, Eubacterium, Clostridium, Streptococcus
tet (33) Efﬂux 1,224 AJ420072 22940..24163 Corynebacterium
tet (34) Enzymatic 465 AB061440 306..770 Aeromonas, Pseudomonas, Serratia, Vibrio
tet (35) Efﬂux 1,110 AF353562 2213..3322 Stenotrophomonas, Vibrio
tet (36) Ribosomal
protection
1,923 AJ514254 2534..4456 Bacteroides, Clostridium, Lactobacillus
tet (37) Enzymatic 327 AF540889 1..327 Uncultured
tet (38) Efﬂux 1,353 AY825285 1..1353 Staphylococcus
tet (39) Efﬂux 1,188 AY743590 749..1936 Acinetobacter
tet (40) Efﬂux 1,221 AM419751 14211..15431 Clostridium
tet (41) Efﬂux 1,182 AY264780 1825..3006 Serratia
tet (42) Efﬂux 1,287 EU523697 687..1973 Bacillus, Microbacterium, Micrococcus, Paenibacillus, Pseudomonas,
Staphylococcus
tet (43) Efﬂux 1,560 GQ244501 60..1619 Uncultured
tet (44) Ribosomal
protection
1,923 FN594949 25245..27167 Campylobacter
Adapted from http://faculty.washington.edu/marilynr/
et al., 2009; Aune and Aachmann, 2010; Burton and Dubnau,
2010).
CONJUGATIVE ELEMENTS (PLASMIDS)
Typically plasmids are extra chromosomal elements that contain
their own origin of replication. They have been found in almost
all bacterial genera and the simplest of these elements just contain
an origin of replication and genes encoding replication functions,
e.g., see Chambers et al. (1988). Plasmids also commonly contain
an origin of transfer and genes encoding functions that allow them
to transfer to new hosts via conjugation (Smillie et al., 2010). Plas-
mids that harbor conjugation genes are called conjugative and
plasmids that only contain an origin of transfer (oriT ) but no
conjugation genes are called mobilizable as they can make use of
the conjugation functions of conjugative plasmids to transfer to a
new host.
In addition to functions involved in replication and transfer
plasmids commonly encode resistance to antibiotics. If a resistance
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Table 7 | Acquired trimethoprim resistance genes.
Gene Sub-family Gene(s) included Length
(nt)
Accession
number
Coding
region
Genera
dfrA1 dfrA1-group dhfrIb, dfr1, dhfrI 474 X00926 236..709 Actinobacter, Enterobacter, Escherichia, Klebsiella,
Morganella, Proteus, Pseudomonas, Salmonella,
Serratia, Shigella, Vibrio
dfrA3 489 J03306 103..591 Salmonella
dfrA5 dfrA1-group dhfrV, dfrV 474 X12868 1306..1779 Aeromonas, Enterobacter, Escherichia, Klebsiella,
Salmonella, Vibrio
dfrA6 dfrA1-group dfrVI 474 Z86002 336..809 Escherichia, Proteus, Vibrio
dfrA7 dfrA1-group dhfrVII, dfrVII, dfrA17 474 X58425 594..1067 Actinobacter, Escherichia, Proteus, Salmonella,
Shigella
dfrA8 510 U10186 711..1220 Shigella
dfrA9 534 X57730 726..1259 Escherichia
dfrA10 564 L06418 5494..6057 Actinobacter, Escherichia, Klebsiella, Salmonella
dfrA12 dfrA12-group dhfrXII, dfr12 498 Z21672 310..807 Actinobacter, Aeromonas, Enterobacter, Enterococ-
cus, Citrobacter, Klebsiella, Pseudomonas, Serratia,
Salmonella, Staphylococcus
dfrA13 dfrA12-group 498 Z50802 718..1215 Escherichia
dfrA14 dfrA1-group dhfrIb 474 Z50805 72..545 Achromobacter, Aeromonas, Escherichia, Klebsiella,
Salmonella, Vibrio
dfrA15 dfrA1-group dhfrXVb 474 Z83311 357..830 Enterobacter, Klebsiella, Morganella, Proteus,
Pseudomonas, Salmonella, Vibrio
dfrA16 dfrA1-group dhfrXVI, dfr16 474 AF077008 115..588 Aeromonas, Escherichia, Salmonella
dfrA17 dfrA1-group dhfrXVII, dfr17 474 AB126604 98..571 Actinobacter, Enterobacter, Klebsiella, Pseudomonas,
Salmonella, Serratia, Shigella, Staphylococcus
dfrA18 dfrA19 570 AJ310778 7004..7573 Enterobacter, Klebsiella, Salmonella
dfrA20 510 AJ605332 1304..1813 Pasteurella
dfrA21 dfrA12-group dfrxiii 498 AY552589 1..498 Klebsiella, Salmonella
dfrA22 dfrA12-group dfr22, dfr23 498 AJ628423 325..822 Escherichia, Klebsiella
dfrA23 561 AJ746361 6743..7303 Salmonella
dfrA24 558 AJ972619 83..640 Escherichia
dfrA25 dfrA1-group 459 DQ267940 54..512 Citrobacter, Salmonella
dfrA26 552 AM403715 303..854 Escherichia
dfrA27 dfrA1-group dfr 474 EU675686 2543..3016 Escherichia
dfrA28 dfrA1-group 474 FM877476 116..589 Aeromonas
dfrA29 dfrVII, dfrA7 472 AM237806 615..1086 Salmonella
dfrA30 dhfrV 474 AM997279 705..1178 unknown
dfrA31 dfr6 474 AB200915 1832..2305 Vibrio
dfrA32 dfrA1-group 474 GU067642 535..1008 Laribacter, Salmonella
dfrA33 dfrA12-group 498 FM957884 88..585 Unknown
dfrB1 dhfrIIa, dfr2a 237 U36276 717..953 Aeromonas, Bordetella, Escherichia, Klebsiella
dfrB2 dhfrIIb, dfr2b 237 J01773 809..1045 Escherichia
dfrB3 dhfrIIc, dfr2c 237 X72585 5957..6193 Aeromonas, Enterobacter, Escherichia, Klebsiella
dfrB4 dfr2d 237 AJ429132 69..305 Aeromonas, Escherichia, Klebsiella
dfrB5 dfr2e 237 AY943084 2856..3092 Pseudomonas
dfrB6 237 DQ274503 394..630 Salmonella
dfrB7 237 DQ993182 244..480 Aeromonas
dfrB8 249 GU295656 1048..1296 Aeromonas
dfrC dfrA 486 Z48233 337..822 Staphylococcus
dfrD 489 Z50141 94..582 Listeria, Staphylococcus
dfrG 498 AB205645 1013..1510 Enterococcus, Staphylococcus
dfrK 492 FM207105 2788..3279 Staphylococcus
Partly adapted from Grape (2006), Partridge et al. (2009).
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gene is on a conjugative or mobilizable plasmid then it has the
potential to transfer to new hosts. Some plasmids have a broad
host range and can transfer between different species whereas oth-
ers have amuch narrower host range and are conﬁned to one genus
or species. There are also plasmids that have the capability of trans-
ferring to a particular host but cannot replicate in the new host or
do not replicate well. In these circumstances the plasmid may be
lost, however if it contains a resistance gene on a transposon this
genetic element can translocate to the bacterial chromosome and
be maintained in the absence of the plasmid. Therefore a plasmid
does not necessarily need to be maintained in a particular host in
order to contribute to the spread of resistance.
Both circular and linear plasmids have been described. Circular
plasmids have in general been more intensively investigated then
linear plasmids. This probably reﬂects the relative ease which they
can be separated from the bacterial chromosome. Nonetheless lin-
ear plasmids have now been relatively well characterized and have
been shown to convey advantageous phenotypes on the host. Like
circular plasmids linear plasmids are often capable of conjugation
(Meinhart et al., 1997; Chaconas and Kobryn, 2010).
Some (resistance) plasmid types cannot coexist in a microbial
cell and this fact gave rise to the division into incompatibility
groups (Couturier et al., 1988). Four major groups have been
deﬁned on the basis of genetic relatedness and pilus structure:
IncF group (containing IncC, IncD, IncF, IncJ, and IncS), IncI
group (including IncB, IncI, and IncK), IncP group (consisting of
IncM, IncP, IncU, and IncW), and Ti.
CONJUGATIVE ELEMENTS (INTEGRATIVE)
The integrative conjugative elements (ICE), also called conjugative
transposons (Roberts et al., 2008), like the conjugative plasmids
contain an origin of transfer and the genes required to make the
conjugation apparatus. Unlike plasmids these elements do not
contain an origin of replication and have to integrate into a repli-
con in order to be maintained. This replicon can be either plasmid
or chromosome. This gives them an advantage over plasmids as
they do not have to have replication machinery that is compatible
with the host so tend to have a larger host range than plasmids.
Integrative conjugative elements are a highly heterogeneous
group of genetic elements with different properties and host
ranges. However in general they do have a modular organiza-
tion, i.e., a conjugation, recombination, regulation, and accessory
modules. The latter commonly contains genes encoding AR.
There are also integrative elements that do not contain the con-
jugation region but can by mobilized by co-resident conjugative
ICE or conjugative plasmids. Again these can mediate the spread
of AR. There have been a number of comprehensive reviews in
this area (Roberts and Mullany, 2009; Frost and Koraimann, 2010;
Wozniak and Waldor, 2010).
TRANSDUCTION
There have been examples of AR genes, and even entire mobile
genetic elements, being mobilized by transduction (Willi et al.,
1997; Del Grosso et al., 2011). Transduction is a process in which
the phage particles are packaged with bacterial DNA instead of
phage. There are two type of transduction, generalized in which
any segment of bacterial DNA can be packaged into the phage
head, and specialized, in which the DNA adjacent to the phage
insertion site is packaged.
TRANSLOCATION WITHIN GENOMES
The simplest of themobile genetic elements are insertion sequence
(IS). These elements just consist of the gene required for element
mobility and the inverted repeat at the ends of the element. IS
elements can be as short as 1Kb (Siguier et al., 2006). When
these elements contain accessory genes not involved in element
translocation they are called transposons. A simple transposon
will contain an accessory gene (often encoding AR) together
with the transposase (for examples of each type of element see
Roberts et al., 2008). There are more complex classes of trans-
posons that move using different mechanisms including class II
transposons.
The transposons mentioned above are not capable of conjugal
transfer to other bacteria and in order for them to be disseminated
they need to be contained within a conjugative element. However
some of ICE elements as well as being able to transfer to new
hosts (see above) are also able to transpose to new genomic sites.
Their ability to use different integration sites in the chromosomes
depends on the type of recombinases they contain. For example
Tn916 can use a large number of different integration sites in
most hosts (reviewed in Roberts and Mullany, 2009). However
some elements are highly site-speciﬁc such as Tn916 (Wozniak
and Waldor, 2010). Presumably elements like Tn916 have evolved
to use different integration sites in order to increase their host
range. Elements that can only use a particular number of inser-
tion sites are limited in the hosts they can use if the site is mutated
or occupied.
GENE CAPTURE ELEMENTS
Integrons are genetic elements that include components of a site-
speciﬁc recombination systemenabling them to capture andmobi-
lize genes, in particular AR determinants (Stokes and Hall, 1989;
Rechia and Hall, 1995; Fluit and Schmitz, 1999; Depardieu et al.,
2007). They harbor an intI gene, encoding a site-speciﬁc integrase
of the tyrosine recombinase family that carries out recombination
between two distinct target sites, i.e., an attI recombination site
and a 59-base element (attC site) where attI is the target site for
cassette integration and a promoter (Hall and Stokes, 1993; Hall
and Collis, 1995; Rechia and Hall, 1997; Mazel, 2006). In contrast
to transposons integrons are not ﬂanked by repeat sequences, in
addition they do not include any genes encoding proteins that
catalyze their movement. HGT of integrons to other bacteria is
mostly mediated by plasmids or transposons.
The intI genes have been used as a basis for grouping integrons
into ”classes.” Currently, four classes are recognized; those carry-
ing intI1 are deﬁned as class 1, intI2 as class 2, intI3 as class 3, and
intI4 as class 4 (Carattoli, 2001; Partridge et al., 2009).
FACTORS INFLUENCING ACQUISITION OF MOBILE GENETIC ELEMENTS
The ability of mobile genetic elements containing AR genes to
spread is modulated by a range of factors including, selective pres-
sures in the environment,host factors, andproperties of the genetic
elements themselves. Each of these factorswill be examined in turn
in the next sections.
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Speciﬁc host encoded factors
Bacteria have a number of systems that protect them from incom-
ingDNA, including restriction/modiﬁcation systems andCRISPR-
Cas systems (Makarova et al., 2011). These systems although
mechanistically very different have the same end point of iden-
tifying and destroying foreign DNA. Restriction systems work by
identifying particular sequences in the incoming DNA that have
not been protected by methylation and digesting them. CRISPRs
act as a memory of past infection by a mobile element and can
destroy that element if the bacterium encounters it again. Both
these systems can be effective in stopping the spread of phage,
ICE, and plasmids.
A speciﬁc host factor that attracts mobile elements has been
documented in the pheromone responsive systems, in which a
plasmid less recipient secrets a pheromone to which plasmids con-
taining strains respond and transfer their plasmid to the recipients
(Palmer et al., 2010).
None speciﬁc host factors
Some none speciﬁc factors that can act as barriers to HGT have
been eluded to above such as not having the target site for a par-
ticular ICE or having incompatible replication systems that stop
plasmids replicating in a particular host. Also the architecture of
the cell surface my not allow the conjugation systems of all mobile
elements towork productively.Additionally onemember of amat-
ing pair may produce inhibitory substances. Bacteria produce a
number of antimicrobial products the most common being the
peptide antibiotics. The best understood are the colicins produced
by E. coli. Gram-positive bacteria also produce a diverse array of
antimicrobial peptides (Riley and Wertz, 2002).
Genetic element encoded factors
Mobile genetic elements have a plethora of ways to overcome
bacterial defense systems. Many plasmids and ICE encode anti-
restriction proteins that as the name suggests inactivate the host
restriction system allowing the element to enter the new host
and survive. Also many mobile genetic elements do not have
many restriction enzyme recognition sites so that they avoid
the attention of the restriction enzymes. Some, including the
common Tn916-like family of conjugative transposons, encode
anti-restriction proteins which have been shown to mimic DNA
and are recognized by the restriction enzyme. The anti-restriction
protein ArdA from Tn916 is one of the best characterized
(McMahon et al., 2009).
Many transposons and ICE can transpose into essential genes.
If this happens the hostwill die, to get around this somemobile ele-
ments are site-speciﬁc or preferentially target inter-genic regions
(Cookson et al., 2011). Also most transposable elements (includ-
ing ICE) are tightly regulated so that they only transpose at low
frequency or transpose when the bacteria are stressed, such as
antibiotics in their environment (reviewed in Roberts and Mul-
lany, 2009; Wozniak and Waldor, 2010). For example members of
the CTndot family of ICE transfer at a much higher frequency in
the presence of tetracycline (the antibiotic to which they encode
resistance). This is an advantageous response for both the element
and the host bacteria (Moon et al., 2005).
Environmental factors
All the factors outlined in the previous sections are important
in modulating the spread of AR but obviously if antibiotics are
present in the environment there is strong selective pressure for
spread of resistance and those factors that promote the spread of
resistance will be selected for and those stopping the spread of
mobile elements selected against.
Gene transfer is also more likely in environments where bac-
teria are in close proximity to each other and in relatively high
density such as the gut and oral cavity. In order to control the
spread of resistance it is important to have an understanding of
the molecular biology of the different mobile genetic elements and
of the ecology of the environments in which spread is likely.
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